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Summary 
 
Acute myeloid leukemia (AML) is a heterogenous hematopoietic disorder which 
includes a number of categories and many subtypes. The incidence rate correlates 
with age showing higher incidence rate for individuals above the age of 65. Patients 
with AML have worse 5-year survival rates compared to other subtypes of leukemia, 
such as acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 
chronic lymphocytic leukemia (CLL).  
Despite many considerable advances in the field of immunotherapy, such as chimeric 
antigen receptor (CAR) T cells, checkpoint inhibitors, dendritic cell vaccination, T 
cell-recruiting antibody constructs and antibody-drug conjugates, clinical 
immunotherapy of AML to date has failed to show the same efficacy seen in other 
types of leukemia. In addition, on-target off-leukemia toxicity remains a challenge. 
Thus, identification of more suitable target antigens for immunotherapy might 
improve the therapeutic efficacy of immunotherapy in AML and ultimately improve 
over outcome for this disease. 
The original „Cell Surface Capturing“(CSC) technology (Glyco-CSC) and it‘s variants 
(Cys-Glyco-CSC and Lys-CSC) technology are Mass spectrometry-based 
technologies which offer the advantage of multiplexed and unbiased detection of cell 
surface proteins independently from existing antibody collections. They provide the 
possibility to identify the entirety of surface proteins expressed on living cell 
populations. However, direct processing of primary leukemia samples has been 
limited by the substantial number of viable cells needed for the CSC-workflow. We 
therefore addressed this issue by improving the technique including the use of our ex 
vivo culture system. This allowed for an unbiased, direct assessment of primary AML 
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patient samples and thus enabled us to interrogate the AML surfaceome in clinically 
relevant samples. Primary cells from patients with newly diagnosed or relapsed AML 
were cultured in our ex vivo co-culture system as previously described (Krupka et al. 
2014) using MS-5 feeder cells. After 3 days, non-adherent cells were harvested and 
immediately subjected to the CSC-workflow. Glyco-CSC and its variants 
Cys-Glyco-CSC and Lys-CSC were initially performed as described by Wollscheid 
and colleagues (Wollscheid et al. 2009 and Bausch-Fluck et al. 2012) and 
subsequently modified to improve the yield on AML samples. CSC samples were 
analyzed by tandem mass spectrometry on an Orbitrap Elite instrument and modified 
peptides were identified using MaxQuant software. 
To enhance the number of successfully identified surface proteins, we also adapted 
the original CSC protocol. These modifications doubled the yield in identified 
proteins from AML cell lines from initially 125 to 252. More importantly, the 
modifications increased the specificity of the assay significantly. In the original 
Glyco-CSC experiments, only 54% of all identified peptides displayed a mass shift 
(of 0.984 Da) associated with successful N-glycosylation and had a transmembrane 
domain or a signal peptide annotated in UniProt. After modification of the protocol, 
80.4% of all peptides fulfilled these criteria. The modified protocol was therefore 
used for all primary samples. 5 representative primary patient samples from initial 
diagnosis and 2 samples from relapsed disease were analyzed. All samples yielded 
sufficient viable cell numbers after ex vivo culture and could successfully be 
subjected to the CSC workflow. We identified a total of 719 surface proteins fulfilling 
all filter rules. 22.9% of these proteins had CD annotations. Next, we only considered 
proteins that were detected by CSC in at least half of the primary patient samples 
tested. In addition, proteins were filtered to eliminate targets that are abundantly 
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expressed on normal human hematopoietic stem and progenitor cells as well as 
relevant healthy tissue using publicly available transcriptome databases. 85 proteins 
were selected as potential candidates for manual screening. Of note, the expression 
of several antigens currently under investigation for AML immunotherapy (i.e. CD33, 
CD123, CD135, CLL-1) were detected by the method. We selected 5 promising 
novel candidate markers previously not described as relevant targets in AML. These 
were assessed by FACS analysis in independent patient samples. 4/5 of our novel 
targets showed uniform expression in all independent primary AML samples tested
(defined as MFI ratio >1.5).
In conclusion, improvements in the CSC-Workflow combined with our ex vivo culture 
system allowed for the successful identification of the AML surfaceome from primary 
patient samples without the necessity of xeno-amplification. We identified 5 novel 
targets, 4/5 were found to be uniformly expressed in independent primary AML 
samples. These candidates are now being evaluated further as potential targets for 
antibody and CAR based immunotherapy in AML.
*  A  majority  of  this  "Summary"  part  was  submit  to  ASH,  Blood   2017   130:3968, 
which I  am the second author. Slightly changes have been made after more  clinical 
data was carried out from AML patient samples.
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Zusammenfassung 
Akute myeloische Leukämie (AML) ist eine genetisch und klinisch heterogene 
Erkrankung. Die Inzidenz der Erkrankung korreliert mit dem Alter und ist deutlich 
erhöht in Individuen über dem Alter von 65 Jahren. Verglichen mit anderen 
Leukämien – akute lymphatische Leukämie (ALL), chronische myeloische Leukämie 
(CML) und chronisch lymphatische Leukämie (CLL) – verbleibt die Prognose für 
Patienten mit AML deutlich schlechter. Trotz deutlicher Fortschritte auf dem Feld der 
Immuntherapie und entsprechenden Anstrengungen, chimäre antigen-rezeptor T 
Zellen, Checkpoint-Inhibitoren, dendritische Zell-Vakzinierungen, T Zell 
rekrutierende Antikörperkonstrukte sowie Antikörper-toxin-Konjugate gegen AML 
einzusetzen, ist der klinische Erfolg für Patienten mit AML bislang begrenzt. Ein 
möglicher Grund ist das die bislang verwendeten Zielantigene auf AML-Zellen 
entweder keine effiziente Eliminierung der malignen Zellen ermöglichen oder eine 
erhöhte Toxizität gegenüber gesunden Zellen aufweisen. Daher besteht ein 
erhebliches Interesse an der Identifikation von geeigneteren Antigenen zur 
Entwicklung von immuntherapeutischen Strategien.  
Die „Cell Surface Capture“ (CSC) Technologie erlaubt die 
Massenzytometrie-basierte Identifikation  der Gesamtheit der 
Zell-Oberflächenproteine (das sog. „Surfaceome“), unabhängig von bestehenden 
Antikörperkollektionen. Bislang war eine direkte Anwendung dieser Technologie auf 
primäre Leukämieproben von Limitationen bezüglich der notwendigen Zellzahlen 
begrenzt. Wir haben diesen Aspekt durch die Verwendung unseres ex vivo 
Kultursystems (Krupka et al., 2014) adressiert. Primäre Patientenproben von 
Patienten mit neu diagnostizierter oder rezidivierter AML wurden mit MS-5 
Stromazellen kokultiviert und nach drei Tagen konnten viable, nicht-adhärante 
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Zellen der CSC Technologie zugeführt werden. Die CSC Proben wurden mittels 
Tandem Massenspektrometrie auf einem Orbitrap Elite Instrument detektiert und 
mittels MaxQuant software ausgewertet.  
Um die Anzahl der erfolgreich identifizierten Proteine zu erhöhen, haben wir zudem 
das vorhandene CSC-Protokoll (Wollscheid et al. 2009 and Bausch-Fluck et al. 2012) 
modifiziert. Durch diese Modifikationen konnten wir die Anzahl der identifizierten 
Proteine auf AML Zelllinien von initial 125 auf 252 erhöhen. In diesem Kontext ist 
jedoch noch relevanter, dass die Modifikationen auch zu einer Erhöhung der 
Spezifität der Technologie führen konnte. So fand sich initial die mit einem für die 
korrekte N-Glycosylation charakteristische Massenverschiebung (0.984 Da) in nur 
54% aller identifizierten Peptide. Nach Einführung der Protokoll-Modifikationen 
erfüllten 80.4% aller identifizierten Peptide dieses Kriterium. Das modifizierte 
Protokoll wurde daher bei allen primären AML Proben eingesetzt. 
5 repräsentative Patienproben zum Zeitpunkt der Primärdiagnose sowie 2 Proben 
von Rezidivfällen wurden analysiert. Von allen Proben konnten ausreichende 
Zellzahlen der CSC-Technologie zugeführt werden. 
Wir konnten in Summe 719 Oberflächenproteine identifizieren. 22.9% dieser 
Proteine waren mit Cluster of Differentiation (CD) Annotationen versehen. In einem 
nächsten Schritt wurden diejenigen Antigene Eliminiert, die entweder auf weniger als 
der Hälfte der analysierten Proben nachweisbar waren oder eine hohe Expression 
auf gesunden hämatopoetischen Stamm- und Vorläuferzellen sowie relevante 
Organe des nicht-hämatopoetischen Systems zeigten.  
84 Proteine wurden als potentielle Kandidaten für ein manuelles Screening 
identifiziert. Interessanter Weise wurde durch unsere Methode mehrere Antigene, 
die derzeit als potentielle Zielantigene für immuntherapeutische Strategien 
Zusammenfassung 
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untersucht weden (CD33, CD123, CD135, CLL-1). Wir wählten 6 vielversprechende, 
neue Antigene, die bislang nicht als relevante Zielantigene in der AML beschrieben 
worden sind, aus. Für 4/5 Antigene konnte eine relevante Expression auf 
unabhängigen AML Patientenproben mittels FACS (definiert als MFI ratio >1.5) 
nachgewiesen werden. 
Zusammenfassend, konnten wir durch Verbesserungen des CSC-Protokolls 
gemeinsam mit der Verwendung unseres ex-vivo Kultursystems erfolgreich das 
Surfaceome in primären AML Proben identizieren. Wir konnten 5 potentiell relevante 
Zielantigene identifizieren, 4/5 ließen sich zudem mit einer relevanten Expression 
auf unabhängigen AML Patientenproben nachweisen. Diese Kandidatenantigene 
werden nun weiter bezüglich Ihrer Eignung als Zielstrukturen für Antikörper- oder 
CAR-T Zell-basierte Immuntherapie evaluiert 
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1. Introduction 
 
1.1 Leukemia and acute myeloid leukemia   
Leukemia is a group of cancers caused by malignant clonal expansion of 
hematopoietic stem- and precursor cells. Alfred-Armand-Louis-Marie Velpeau, an 
anatomist and surgeon, described leukemia for the first time in 18271,2, though it is 
possible that leukemia had already been seen as early as 18111,3. Leukemia may 
occur in every stage of people’s whole life, most often in older adults, but it is the 
most common cancers in young children. The incidence and death rate are low 
before age 60, 16.8 and 5.8 (rate is per 100,000 per year), respectively. But there is a 
rapid increase from age 65 to 85+, with incidence rates increasing from 38.3 to 87.5 
and death rates increasing from 17.7 to 84.04.   
Leukemia can be divided into 4 main types: acute lymphoblastic leukemia (ALL), 
acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic 
myeloid leukemia (CML)5,6. ALL is the most common childhood leukemia, about 75% 
of all ALLs were accounted in children (Figure 1-1 A). By contrast, AML, CLL and 
CML occur mainly in adults. According to data statistics from National Cancer 
Institute (NCI, at the National Institutes of Health (NIH)), AML is the most common 
acute leukemia in adults with a incidence of 4.1/100,000 cases (year 2009-2013)4 in 
the US. Incidence dramatically increases with age, resulting in 19.1/100,000 cases in 
the age group 65+ (Figure 1-1 A)4. Despite some improvement since 1975, 5-year 
relative survival rate for AML patients remain low for now (26.8%) (Figure 1-1 B). In 
addition, survival rates correlate with age, resulting in a 5-year relative survival rate of 
6.3% in patients aged above 65 while younger patients display 5-year survival rates 
of 44.8% (Figure 1-1 C and D). One significant reason is that in spite of remission 
rates of up to 80% after intensive induction chemotherapy, patients with AML have a 
Introduction 
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D 
high risk of disease recurrence. Therefore, more research is needed to improve 
survival rates or achieve long-term cure for the majority of AML patients in the future. 
 
 
  
 
 
 
 
 
 
 
*Data source: https://seer.cancer.gov/csr/1975_2013/sections.html, NCI SEER, all races, both sexes, 1975-2013.
Figure 1-1. Updated data of leukemia. (A) SEER incidence of leukemias show that leukemia occurs 
in every age group. ALL patients are mainly younger children (age<14) while AML, CLL and CML are 
mainly  found  in  adult  patients,  especially those  age  55+. (B)  Great  improvements  have  been  made 
since 1975. Leukemia patients have a much higher 5-year relative survival rate now (62.7%) compare 
to 34.2% in 1975. AML patients have the poorest 5-year relative survival rate (26.8%) while CLL patients display 
a  more favorable prognosis  (85.1%).  (C) With  increased age, survival  rates decrease:  AML  patients  aged  65+ 
have the lowest survival rate, only 6.3%, compare to the other 3 types (D).
Most patients eligible for intensive therapy, excluding acute promyelocytic leukemia, 
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intravenous (i.v.) infusion of cytarabine (7 days) and anthracycline (3 days, mostly 
daunorubicin, alternatively mitoxantrone or idarubicin), 60-80% of younger adults and 
40-60% of older adults (65+) will achieve a complete remission (CR)7-10.  
Despite some improvements, especially for patients below 60 years of age, 50-70% 
of patients achieving first CR are expect to relapse within 3  years11,12. Relapses in 
patients with a continued CR of >5 years are rare (1.16% of all relapses) 13. However, 
prognosis for relapsed or refractory AML (R/R-AML) is especially poor14-16. Many 
factors might contribute to the poor outcomes at relapse, such as cytogenetics, 
unidentified mutations, relapse after hematopoietic stem cell transplant (HSCT), older 
age, and duration of first CR less than 12 months14,17-20. 
The major reason considered to cause relapse in leukemia is a small number of 
leukemic cells still detectable in the patients during or after treatment when a CR 
achieved. These cells have been termed “minimal residual disease” (MRD) or 
“minimal measurable disease”. MRD assays have been established and are 
commonly performed in ALL patients21-24. In AML, MRD assessment is more complex 
due to the genetic as well as phenotypic heterogeneity of the disease. One potential 
target for MRD assessment in AML is are nucleophosmin (NPM1) gene mutations, 
which occur in about 30% patients, which represent the most frequent genetic 
alteration in AML25. More than 50 NPM1 mutations have been found to date. Type A, 
B and D are the three most common variants found in 90% of all mutated cases26-32. 
Fms-like tyrosine kinase 3 (FLT3) internal tandem duplications (ITD) is a second 
commonly affected gene mutation and can be identified in about 25% of all AML 
patients. However, heterogeneity and instability limits its suitability as a MRD 
marker28-38. These examples highlight the fact that AML is a biologically 
heterogeneous disease.  
Introduction 
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Traditional chemotherapy-based treatment of AML patients are unlikely to improve 
outcomes. Various novel immunotherapy strategies are being evaluated in 
pre-clinical and clinical trials, such as chimeric antigen receptor (CARs) T cells39-45, 
dendritic cells (DC) vaccination46-48 and antibody based immunotherapy49-56. Clinical 
results from these functional cells or antibody drugs are expected to further improve 
survival interval and prevent relapse of AML patients. 
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1.2 Advanced cancer therapies 
 
 
Figure 1-2. Current strategies to treat cancers and hematopoiesis disorders. 8 treatment 
strategies were developed to fight against cancer and hematopoiesis diseases to date. Surgery, 
radiation therapy, and chemotherapy are still important choices for many types of cancer, especially 
solid tumors. Immunotherapy and targeted therapy are two most potential strategies for all types of 
cancers, with the development of new/novel therapeutic markers and relevant drugs. Hormone therapy 
is applied to treat gender-special cancer, like breast cancer; while stem cell transplant (SCT) is specific 
for numbers of hematopoiesis diseases, like leukemias. Precision medicine aims to supply personalise 
treatment strategy to the patient based on the rapid development of gene sequencing technology and 
big data, i.e. genome, proteome, transcriptome and metabolome. 
 
The National Cancer Institute (NCI) lists 8 main types of cancer treatment (Figure 
1-2). Besides the 3 conventional strategies (surgery, radiation therapy and 
chemotherapy), 5 more recent strategies are also involved, which are immunotherapy, 
targeted therapy, hormone therapy, precision medicine, and  stem cell transplant 
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(SCT). Currently, cancer patients commonly receive a combination of treatments, 
including surgery (especially for solid tumors such as breast cancer, lung cancer and 
prostate cancer), radiation therapy, chemotherapy, immunotherapy and SCT 
(especially for hematological cancers). Immunotherapy utilizes the host immune 
responses to produce potent cancer destruction; whereas, targeted therapies 
commonly aim to block essential molecular pathways crucial for proliferation and 
maintenance of cancer. But NCI claims that immunotherapy is one type of targeted 
therapies, which possibly indicates that there is obscure boundary between 
immunotherapy and targeted therapy. Since they both are focusing on suitable 
“targets” on tumor cells, immunotherapy and targeted therapy play very important 
roles in the development of new/novel anticancer drug. 
  
1.2.1 Cancer immunotherapy  
 
Briefly, the aim of cancer immunotherapy is to utilize a patient’s own immune system 
to treat cancer. Four main types strategies are accounted for cancer therapy: 1) 
antibody therapy; 2) cellular immunotherapy (i.e. DC and CAR T cells); 3) cytokine 
therapy (interleukin and interferon); 4) Therapeutic vaccines (Figure 1-2). Cancer 
immunotherapy has a long history in its development (Figure 1-3)57,58 and now is 
given rise to new options for  cancer treatment57,59-65.  
In 1796, Edward Jenner produced the first vaccine with cowpox to against smallpox57. 
About 100 years later, Paul Ehrlich firstly named the “slide-chain” theory on 189766, 
but it was replaced by “receptor” in 190067 and it was accepted by doctors and 
scientific researchers and still in use now. Meanwhile, Coley’s toxins (also called 
Coley’s treatment) was developed by William Coley, a bone surgeon, to treat with 
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different types of cancer from 1893 to 196368,69. But it did not show more promising 
results in several small clinical trials. Chemotherapy and HSCT were developed from 
1940s to 1960s70-72. More and more important discoveries came up after the 
tumor-specific antigen was found in mice73, including the discovery of DC74,75, first 
report of treatment lymphoma with monoclonal antibody76, research on IL-2 and 
IFN-α on human77,78. In the late 20th century, Steven Rosenberg et al. had introduced 
immune cell therapy for cancer. They received a low tumor regression rate (2.6-3.3%) 
in 1205 metastatic cancer patients79,80. The first experimental DC vaccine81 and the 
first set of tumor-specific antigens from melanoma patient82 were studied in the 
1990s.  
FDA approved drugs, especially for immunotherapy and targeted therapy, promoted 
the improvement of cancer therapy since the 1980s83-88. With the coming of the 21st 
century, totally 395 new therapeutic drugs had been proved by FDA between 2001 
and 2015, among which 112 (28.4%) were used for treatment of hematologic, 
oncologic, or immune-modulating disease89,90. Figure 1-3 listed some selected FDA 
approval drugs from 2000 to 2017 and information of those drugs can be found online 
(FDA Approved drugs: Hematology/Oncology (Cancer) Approvals & Safety 
Notifications): 
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm.  
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1.2.2 Targeted cancer therapy  
 
4 different types of cancer therapy are commonly involved in the current treatment 
with anticancer drugs: chemotherapy, hormonal therapy, targeted therapy and 
immunotherapy (Figure 1-2)91. After the first tumor-specific antigens were identified 
and isolated from melanoma patient82, the race was on to target them as therapeutic 
vaccines. Technically, targeted cancer therapy is considered as a special type of 
chemotherapy. However, different from conventional chemotherapy, targeted cancer 
therapy makes combination with specific proteins involved in tumorigenesis and show 
cytostatic instead of cytotoxic92,93.  3 mainly types of drugs are developed in targeted 
cancer therapies: 1) monoclonal antibodies, 2) small molecule inhibitors and 3) 
immunotoxins (Figure 1-2)93.  
NCI summed up 7 types of targeted therapies for cancer treatment, including 
hormone therapies, signal transduction inhibitors, gene expression modulators, 
apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery 
molecules. Sometimes, cancer vaccine and gene therapy are also considered as 
targeted therapies since they attack and interfere with the growth of cancer cells. 
Taking cancer vaccine as an example, in 1993, Glenn Dranoff developed the first 
therapeutic vaccine comprised of cancer cells genetically modified to secrete 
granulocyte-macrophage colony-stimulating factor, shorted as GVAX94. GVAX and 
CRS-207, a supplemental vaccine, were granted by FDA in 2015 as 2 vaccines in 
patients with metastatic pancreatic adenocarcinoma95. GVAX can be an option to 
treat many other cancers, such as melanoma, ovarian, NSCLC and prostate 
cancer96-99.  GVAX also showed effective roles in post-transplantation AML and CLL 
studies100,101.  
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Targeted therapies had been expected less toxic than traditional chemotherapy since 
they commonly target with cancer cells rather than normal cells. But scientists and 
doctors did find side effects during the research and treatment. Moreover, there are 
still limitations of targeted cancer therapies for cancer treatment, such as drug 
resistant; not all cancers respond to targeted therapy; the drugs are expensive or not 
yet developed for specific types of cancer. Mutation of target and new pathway 
discovered for cancer survival would cause the resistant, which makes targeted 
cancer therapies most often used in combination with more other targets102, or other 
strategies, such as immunotherapy103,104, surgery, chemotherapy and/or radiation 
therapy.  
New anti-cancer drugs are urgent need to treat those patients. FDA had approved 
169 drugs for target cancer therapy since December 31, 2017. Among them, 53 
drugs (31.4%) were approved to treat with hematologic cancers, 19 for leukemia, 17 
for lymphoma and 6 for multiple myeloma (MM), (Figure 1-4, Table 1-1). Some drugs 
shared the same target and some of them have been approved for more than one 
type of cancer105. Nivolumab and pembrolizumab are two widely used checkpoint 
inhibitors that targeted programmed cell death protein 1 (PD-1) to block a signal 
which prevent active T cells from eliminating cancer cells. The FDA has approved 
these to treat several specific types of cancer, including head and neck cancer (HNC), 
melanoma, lymphoma and lung cancers. Nivolumab also had been approved for the 
treatment of advanced form of kidney cancer in 2015 and more recently for urothelial 
carcinoma, in February, 2017. Anti-cluster of differentiation antigen (CD) 20 antibody, 
rituximab, was approved for the treatment of both previously untreated and previously 
treated CLL and certain types of B-cell non-Hodgkin lymphoma (NHL). Another 
anti-CD20 antibody, obinutuzumab, have been approved to treat previously untreated 
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CLL  and  R/R Follicular  Lymphoma (FL).  Idelalisib,  acts  as  a 
phosphatidylinositol-3-kinase-delta  (PI3Kδ)  inhibitor,  has  been  approved  for  the 
treatment of recurred CLL and NHL patients (Table 1-1).
Side  effects,  like  skin  problems  and  blood  pressure,  still  exist  though  most 
researchers had expected that targeted cancer therapies would show less cytotoxic
than conventional chemotherapy.   But some side effects have been noticed that they 
were linked to better outcomes106,107. Children and adults patients may have different
108side effects to specific target therapy . Many mutations and uncertain changes may 
involve in the development of cancer makes it a multifactorial disease. Different types 
of  cancer  may  own  different  critical  targets.  Therefore,  targeting  one  specific 
molecular  target  or  pathway  may  not  be  the  final  option.  Many  targeted  therapies 
have  been  studied  in  combination  with  established  chemotherapies  or  more  than  2 
critical targets. Bevacizumab is the first angiogenesis inhibitor drug approved to treat 
numerous types of cancer. It didn’t improve patient survival rate as a monotherapy for 
metastatic  colorectal  cancer,  however,  it  provided  a  2.5  months  benefit  in
progression-free  survival  and  overall  survival  when  combination  with  FOLFOX4
109(oxaliplatin/5-FU/leucovorin) . In addition,  blockade  of  co-inhibitory  pathways,  like 
PD-1,  PD-L1  and  cytotoxic  T-lymphocyte-associated  protein  4  (CTLA-4),  also
provided  an  effective  and  durable  cancer  immunotherapy  in  several  types  of
110 112cancer - . More recently, FDA granted accelerated approval to pembrolizumab
(in  combination  with  pemetrexed  and  carboplatin)  for  the  treatment  of  previously 
untreated NSCLC patients. There is still a long way ahead for all cancer treatments 
besides the achievements researchers have now. Side effects, therapeutic index and 
myriad  possibilities  are  challenges  of  combination  therapies,  which  would  be 
overcame and improved by scientific researchers and clinical doctors in the future.  
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*Data sources:  
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm 
https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-shee
t 
Figure 1-4. FDA approved drugs for targeted cancer therapy. Totally 169 drugs (or combined 
drugs) had been approved by FDA for targeted cancer therapy (some of them have been proved for 
more than one specific type of cancer). 53 drugs (31.4%) were approved for hematologic malignancies. 
(Reviewed: December 31, 2017) 
Abbreviations: DFSP, Dermatofibrosarcoma protuberans; ET/NET, Endocrine/neuroendocrine tumors; 
GCTB, Giant cell tumor of the bone; HNC, Head and neck cancer; GIST, Gastrointestinal stromal 
tumor; MD/MPDs, Myelodysplastic/ myeloproliferative disorders; MM, Multiple myeloma; NB, 
Neuroblastoma; OEC/FTC/PPC, Ovarian epithelial/fallopian tube/primary peritoneal cancers; SM, 
Systemic mastocytosis; STS, Soft tissue sarcoma. 
 
Table 1-1. FDA approved targeted therapy drugs for hematologic malignancies. (Reviewed: 
December 31, 2017) 
 
Drugs FDA approved indication(s) Target(s) 
Leukemia   
Tretinoin/ATRA (Vesanoid®) APL, AML RARs 
Imatinib Mesylate (Gleevec®) ALL (Ph+), CML (Ph+) ABL, KIT, PDGFR 
Dasatinib (Sprycel®) ALL (Ph+), CML (Ph+) ABL 
Nilotinib (Tasigna®) CML (Ph+) ABL 
Bosutinib (Bosulif®) CML (Ph+) ABL 
Rituximab (Rituxan®) CLL CD20 
Alemtuzumab (Campath®) CLL CD52 
Ofatumumab (Arzerra®) CLL CD20 
Obinutuzumab (Gazyva®) CLL CD20 
Ibrutinib (Imbruvica®) CLL BTK 
Idelalisib (Zydelig®) CLL PI3Kδ 
Blinatumomab (Blincyto®) ALL (Ph-) CD3, CD19 
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Venetoclax (Venclexta™) CLL (del[17p]) BCL2 
Ponatinib Hydrochloride (Iclusig®) 
CML (Ph+)T315I mutation 
ALL (Ph+)T315I mutation 
FLT3, VEGFR2, 
ABL, FGFR1-3 
Midostaurin (Rydapt®) AML (FLT3
+
) FLT3 
Combination of rituximab and 
hyaluronidase human 
CLL and diffuse large B-cell lymphoma CD20 
Blinatumomab (Blincyto®) ALL (Ph+) CD3, CD19 
Enasidenib (Idhifa®) AML (IDH2 mutation) IDH2 
Liposome-encapsulated combination 
of daunorubicin and cytarabine 
t-AML or AML-MRC DNA/RNA 
Inotuzumab ozogamicin 
(Besponsa®) 
ALL CD22 
Tisagenlecleucel (Kymriah®) ALL CAR T cell therapy 
Gemtuzumab ozogamicin 
(Mylotarg®) 
AML CD33 
Dasatinib (Sprycel®) CML (Ph
+
), in the chronic phase ABL 
Bosutinib (Bosulif®) CML (Ph
+
), newly-diagnosed chronic 
phase 
ABL 
Nilotinib (Tasigna®) CML (Ph+), updated ABL 
Lymphoma   
Ibritumomab Tiuxetan (Zevalin®) NHL CD20 
Denileukin Diftitox (Ontak®) CTCL CD25 
Brentuximab Vedotin (Adcetris®) ALCL, HL CD30 
Rituximab (Rituxan®) NHL CD20 
Vorinostat (Zolinza®) CTCL HDAC 
Romidepsin (Istodax®) CTCL HDAC 
Bexarotene (Targretin®) Skin problems caused by CTCL RXRs 
Bortezomib (Velcade®) MCL Proteasome 
Pralatrexate (Folotyn®) PTCL DHFR 
Ibrutinib (Imbruvica®) MCL, NHL BTK 
Siltuximab (Sylvant®) MCD IL-6 
Idelalisib (Zydelig®) FL, SLL PI3Kδ 
Belinostat (Beleodaq®) PTCL HDAC 
Obinutuzumab (Gazyva®) FL CD20 
Nivolumab (Opdivo®) cHL PD-1 
Pembrolizumab (Keytruda®) cHL PD-1 
Combination of rituximab and 
hyaluronidase human 
FL CD20 
Copanlisib (Aliqopa®) FL PI3K-α and PI3K-δ 
Axicabtagene ciloleucel (Yescarta™) R/R large B-cell lymphoma CAR T cell therapy 
Brentuximab Vedotin (Adcetris® ) pcALCL CD30 
Obinutuzumab (Gazyva®) FL CD20 
Acalabrutinib (Calquence®) MCL BTK 
Multiple myeloma (MM)   
Bortezomib (Velcade®) MM Proteasome 
Carfilzomib (Kyprolis®) MM Proteasome 
Ixazomib citrate (Ninlaro®) MM Proteasome 
Panobinostat (Farydak®) MM HDAC 
Elotuzumab (Empliciti™) MM SLAMF7 
Daratumumab (Darzalex™) MM CD38 
 
*Data sources:  
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm 
https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-shee
t 
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1.2.3 AML therapies  
 
A number of immunotherapeutic strategies have been developed113,114. Immune 
checkpoint inhibitors, which were previously studied in various solid tumors115, have 
shown considerable promise in the treatment of AML and other types of hematologic 
malignancies116,117. Hereby, we mainly discuss three types of treatment: 
antibody-based immunotherapy, Immune checkpoint pathways and Immune cells 
(DCs and CAR T cells)-based strategies. 
1.2.3.1 Antibody-based immunotherapy 
Antibody-based immunotherapy demonstrated efficacy by targeting surface antigens 
expressed on tumor or immune cells. Monoclonal antibodies (mAbs) were identified 
as unique tools in clinical diagnosis and basic research investigation after its first 
description in 1975118 and now hare considered as a standard component of cancer 
treatment. CD33 is a cell surface therapeutic target which has been found to be 
broadly expression on AML blasts52. FDA granted accelerated approval to 
Gemtuzumab ozogamicin (GO), an anti-CD33 antibody conjugate, for treatment of 
AML patients who have relapsed following initial chemotherapy in 2000119. 
Subsequently, it was voluntarily withdrawn from the US market in June 2010 since a 
randomized phase 3 study found addition of GO showed no improvement in CR, 
disease-free survival (DFS), or overall survival (OS)120. There still are several clinical 
trials focus on GO (or combined with other drugs) for the treatment of AML patients 
(Table 1-2). SGN-CD33A is another immune-conjugated anti-CD33 antibody that is 
being evaluated in several clinical trials (Table 1-2). SGN-CD33A showed improved 
efficacy compared to GO in xenograft mice models121. Additionally, other antibody 
based therapies are being evaluated in clinical trials, including antibodies targeting 
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CD37, CD45, CD47 and CD123. AMG 330 is a novel bispecific T-cell-engaging 
antibody (BiTE), which belongs to a novel class of cytotoxic drugs derived from 
antibody-based immunotherapy. By targeting both CD33 and CD3, AMG 330 would 
recruit T cells and show effective antibody-mediated cytolysis in ex vivo52 and in 
vivo122 experiments at low effector-to-target (E:T) ratio. AMG 330-regulated 
cytotoxicity and immune responses were significantly enhanced after blocking the 
PD-1/PD-L1 pathway53. CD33 antigen universally expressed on AML blast cells from 
individual patients which indicated CD33 as an useful target for debulking CD33+ 
AML cells. But it is not an ideal target to eradicate all types of AML cells since it was 
still not crystal clear whether, or to what degree, this antigen was displayed on AML 
progenitor and stem cells123, though some data from cDNA microarray showed CD33 
lower expressed on normal hematopoietic stem cells (HSCs) than on AML leukemic 
stem cells (LSCs)124.  JNJ-63709178, another BiTE antibody targets CD123 and 
CD3, was considered to be a candidate drug to eliminate AML stem cells since 
CD123 was presumed widely expressed on those cells.  The first-in-human (FIH) 
phase 1 clinical trial was carrying out by Amgen and Janssen Research & 
Development, LLC, focus on the research of AMG 330 and JNJ-63709178, 
respectively (Table 1-2).  As no AML-specific antigens were identified and BiTE 
antibodies could be highly effective at low target antigen level, target antigens should 
be selected prudently and their expression on regenerative and normal tissues need 
to be assessed carefully.  
1.2.3.2 Immune checkpoint pathways  
Immune checkpoint pathways, particularly the CTLA-4 and PD-1/PD-L1, have 
become promising therapy strategies in both solid and blood cancers110,116,125-127. 
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Several phase 1 or 2 clinical trials start learning on the effect of nivolumab, 
pidilizumab, atezolizumab and ipilimumab for the treatment of AML patients (Table 
1-2). FLT3, also known as CD135, is a surface antigen expressed on many 
hematopoietic progenitor cells. FLT3-ITD is the most common mutation associated 
with AML patients which indicates worse prognosis33. On April 28th 2017, FDA 
approved midostaurin (RYDAPT, Novartis Pharmaceuticals Corp.), in combination 
with standard cytarabine and daunorubicin induction and cytarabine consolidation, for 
the treatment of adult patients with newly diagnosed (AML) who are FLT3 
mutation-positive (FLT3+) (Table 1-1). This is the first FDA approved multi-targeted 
protein kinase inhibitor drug for AML therapy since 1990. The efficacy and safety of 
midostaurin-combined treatments were studied in a randomized phase 3 clinical trial 
of 717 AML patients. The trial showed significant improvement in OS for midostaurin 
received patients compared to placebo treated patients, median months from 16.3 
(placebo) to 20.9 (midostaurin) (HR=0.77, p=0.016)128. AGS62P1 is another novel 
site-specific antibody drug conjugate target FLT3. Its preclinical assessment of 
anti-leukemic activity had been tested with AML and ALL cell lines, in vitro and in 
vivo129,130. Agensys, Inc. sponsored a phase 1 clinical trial to evaluate the safety, 
tolerability, pharmacokinetics and the anti-leukemic activity of AGS62P1 in AML 
patients’ age of year 18 and older (Table 1-2).  
More recently, FDA approved enasidenib, a small molecule inhibitor of isocitrate 
dehydrogenase 2 (IDH2), for the treatment of adult R/R AML patients with an IDH2 
mutation on August 1, 2017 (Table 1-1). With orally treatment with 100 mg of 
enasidenib, 23% of 199 adult AML patients experienced CR or complete response 
with partial hematologic recovery (CRh) lasting a median of 8.2 months 
(NCT01915498). This is the first FDA approval for R/R AML specifically with an IDH2 
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mutation and FDA concurrently approved a companion diagnostic, the RealTime 
IDH2 Assay, used to detect the IDH2 mutation. 
B-cell lymphoma 2 (BCL2) was identified as an apoptosis regulator in 1986 and was 
continuous researched on how its functional roles in cancer biology for more than 20 
years131. Recently, a novel BCL2 inhibitor drug, venetoclax, was reported with a 79% 
overall response rate for all 116 R/R CLL or small lymphocytic lymphoma (SLL) 
patients132.  FDA approved venetoclax as the first drug targets BCL2 for the 
treatment of CLL patients who have a chromosomal abnormality called 17p deletion 
(del[17p]) and who have been treated with at least one prior therapy in April 2016 
(Table 1-1).  AbbVie, which developed the drug in collaboration with Roche, also 
claimed a phase 2 breakthrough designation that combination of venetoclax with 
hypomethylating agents in naïve AML patients.  S 055746 is another candidate 
BCL2 inhibitor drug and now is performing phase 1 trials with AML patients (Table 
1-2).   
 
1.2.3.3 Immune cells (DCs and CAR T cells)-based strategies 
DCs are professional antigen-presenting cells (APCs), and thus usually are 
considered as “nature's adjuvants” for antigen delivery in cancer immunotherapy. 
DC-based vaccines133-136 and immunotherapies136-138 are essential therapy 
approches to induce immune responses through the patients’ own immune system. 
Numerous of leukemia-associated antigens (LAAs), such as FLT3, preferentially 
expressed antigen in melanoma (PRAME) and Wilm’s tumor protein 1 (WT1), were 
identified with the development of the tumor biology and biochemistry. Clinical phase 
1/2 trials on those peptide vaccines also have showed exciting results for AML 
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patients. DCs, however, retain the potential to be more successful than peptide 
vaccines since its antigen delivery properties in cellular and humoral immunity. The 
first clinical study of autologous monocyte-derived DCs on patients was carried out to 
treat AML relapse after autologous SCT139. More recently, 17 of in-remission but at 
high risk with relapse AML patients were administrated with WT1 
mRNA-electroporated DCs that differentiated from CD14+ monocytes. In this phase 
1/2 study, 8 patients reached clinical and molecular remission. Median of OS was 
from 6 months (non-responders) to 52 months (responders), p=0.0007; and median 
of relapse-free survival was 3 months (non-responders) compared to 47 months 
(responders), p<0.0001. Excitingly, two out of three patients, who only got partial 
remission with chemotherapy-refractory disease, achieved CR after 4 vaccinations 
with this cellular product140,141. Other clinical studies also have shown that DC-based 
immunotherapies were safe and improved the survival rate by inducing anti-tumor 
immune responses142.  
Normally, DCs can be generated from hematopoietic precursor cells, monocytes, 
embryonic stem cells and peripheral blood stem cells143,144 with a standard 7-day 
protocol. An improved 3-day protocol developed in our lab to obtain mature DCs from 
monocytes which stimulated by cytokines, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and IL-4 for 48 hours, and subsequently, 
incubated with toll-like receptor (TLR)7/8 agonist-containing maturation cocktail for 
another 24 hours48. A phase 1/2 study (NCT01734304) held by our lab had revealed 
the feasibility and safety of the next-generation DCs for post-remission therapy of 
AML patients145. Delayed-type hypersensitivity (DTH) responses were achieved in 
6/6 patients, and 9/9 patients in updated data at December 2016146, accompanied by 
slight erythema and indurations at the injection site, but no grade III/IV toxicities. 
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Autologous leukemic apoptotic corpse pulsed DCs also showed significantly 
improvement of OS in elderly AML patients (NCT01146262). In this study, most 
patients (19/21) received non-intensive chemotherapy. After 5 vaccines administrated, 
the median of OS was extended from 4.75 months to 13 months, p=0.00947. However, 
another literature showed that 71% (12/17) of patients, the median age was 63 years, 
remain alive without recurrence at a median follow-up of 57 months after treated with 
autologous DCs147. Current DC-based therapy had demonstrated promising results in 
solid, skin and blood cancers114,142,148. Further deeply and widely researches are 
clearly needed with more sophisticated strategies developed, like identification of 
individual patient antigens or mutations.  
CAR T cells are another potent candidate strategy to treat AML and several of other 
types of cancer39,43,45,149,150. CAR T cells were usually engineered by grafting an 
arbitrary specificity onto T cells to increase the specificity of those T cells which could 
be adoptively transferred to cancer patients. Many CD (CD19, CD20, CD22, CD33 
and CD123) and non-CD (IL-13Rα, endothelial growth factor receptor (EGFR), 
carcinoembryonales antigen (CEA) and human epidermal growth factor receptor 2 
(HER2)) targets for CAR T cells were submitted for clinical trials39,149. Many factors in 
the whole immune system, like the regulatory T cells, checkpoints and tumor 
microenvironment, would influence the function of CAR T cells151-153.  
T cell-based immunotherapies, including antibody bases immunotherapy, DC 
vaccines and CAR T cells, together with checkpoint-targeted drugs and standard 
established chemotherapy, mainly shaped the advanced AML therapy114. Some 
approaches might have achieved milestone success, e.g. APL therapy154, but not 
with broadly feasible for treatment with other cancers. The high risk of relapse in AML 
patients, the poor survival rate after chemotherapy and SCT and tolerance ability for 
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individual treatment of patients with SCT prompt researchers to look for more LAAs or 
even the leukemic specific antigens (LSAs). New therapeutic drug or checkpoint 
targets are urgently needed for more promising preclinical and clinical trials, with the 
final purpose to completely eliminate both leukemic cells and leukemic stem cells 
(LSCs).  
High relapse rates and poor prognosis remain challenging in AML, especially 
compared to other subtypes of leukemia (Figure 1-1 B). Current immunotherapeutic 
approaches for AML therapy have had only shown limited success in clinical trials. 
Thus, novel, more specific targets are needed for AML immunotherapy. “Cell Surface 
Capturing” (CSC) technology provide the possibility to identify the whole leukemia 
surfaceome (cell surface proteome) of AML blasts or cell lines. In this study, we 
employed this technology and its variants to discover new targets for AML 
immunotherapy. In addition, the identification of more specific surface markers is also 
likely to improve MRD detection. 
 
Table 1-2. Ongoing clinical trials of antibody/immune checkpoint-based treatments for AML 
patients.  
 
Drug(s) Target(s) NCT trial number Phase 
AMG 330 CD33/CD3 NCT02520427 1 
SGN-CD33A CD33 NCT02326584 1 
SGN-CD33A CD33 NCT01902329 1 
SGN-CD33A CD33 NCT02785900 3 
IMGN779 CD33 NCT02674763 1 
GO (combination) CD33 NCT02473146 2/3 
GO (combination) CD33 NCT02724163 3 
AGS67E CD37 NCT02610062 1 
Yttrium Y 90 CD45 NCT01300572 1 
Hu5F9-G4 CD47 NCT02678338 1 
SGN-CD123A CD123 NCT02848248 1 
KHK2823 CD123 NCT02181699 1 
Talacotuzumab CD123 NCT02472145 3 
JNJ-63709178 CD123/CD3 NCT02715011 1 
AGS62P1 FLT3 NCT02864290 1 
Nivolumab PD-1 NCT02532231 2 
Nivolumab PD-1 NCT02275533 2 
Pidilizumab PD-1 NCT01096602 2 
Atezolizumab PD-L1 NCT02935361 1/2 
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Nivolumab/Ipilimumab PD-1/CTLA-4 NCT02397720 2 
Ipilimumab CTLA-4 NCT01757639 1 
Ipilimumab CTLA-4 NCT02890329 1 
S 055746 BCL2 NCT02920541 1 
 
*Data source : https://clinicaltrials.gov/ 
 
1.3 AML surfaceome and LC-MS-based CSC technology 
 
Surfaceome, also referred to as the cell surface sub-proteome, are proteins that are 
expressed on the cell surface. These proteins represent important cellular functions 
in cell-cell interaction, cell signaling and microenvironment. Cell surface proteins, 
offer great potential as therapeutic targets105. A comprehensive analysis of the 
surface proteome promises to be useful for the identification and validation of novel 
targets, which may be considered for the development of antibody-, DC vaccines-,  
and CAR T cell-based AML therapy. However, until recently, a comprehensive 
mapping of the surface proteins was technologically limited.  
Mass spectrometry (MS)-based technologies offer the advantage of multiplexed and 
unbiased detection of proteins independent of existing antibody collections. The 
original “Cell Surface Capturing” (CSC) technology (Glyco-CSC) and its variants 
(Cys-Glyco-CSC and Lys-CSC) technology provide the ability to identify all surface 
proteins of any cell population155-157. These three strategies were developed based 
on the following features of membrane proteins: 1), most cell surface proteins are 
known or predicted to be glycosylated158,159 (for original CSC); 2), the glycosylated 
peptides often contain cysteine residues within disulfide bridges160,161 (for 
Cys-Glyco-CSC); 3), lysine-contained proteins can be identified by interaction with 
biotin162-164 (for Lys-CSC). Taking advantages of these features, membrane peptides 
can be detected and the associated specific proteins identified. The procedure 
encompasses six steps which are depecited in Figure 1-4. Compared to other 
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strategies, such as lectin-based methods, cell surface shaving, antibody-mediated 
membrane enrichment, silica bead coating method, cell surface biotinylation, 
reversed phase capillary liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS)-based CSC technologies provide increased specificity 
(95%) and thus allow for the mapping of a more representative surfaceome155,165,166.  
 
 
 
 
 
 
 
 
 
 
 
*Figure source : http://www.gundrylab.com/research/#/cellsurfaceproteins/ 
Figure 1-4. Overview of the CSC workflow. Six mainly steps involved in CSC and it’s variant 
technologies: (1) oxidation of reactive protein groups, (2) biocytin hydrazide or NHS-SS-biotin labelling, 
(3) cell lysis, membrane protein collected and digested, (4) affinity purification of glycopeptides, (5) 
enzymatic or reduction release peptides and (6) analysis and identification of peptides. 
 
In a previous study using two AML cell lines, more than 500 membranes were 
identified, including 137 CD antigens160. Another group identified 823 proteins with an 
EZ-link sulfo-NHS-LC-biotin-based protocol; however, only 320 proteins could be 
annotated to the cell surface membrane. Membrane specificity was not high, with a 
percentage of putative membrane proteins in all six samples ranging between 44 and 
53%166. The hematopoietic cell surface marker CD45, the myeloid marker CD33 and 
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granulocyte differentiation markers such as CD11b and CD35 were identified in both 
studies. However, no comprehensive mapping of the surfaceome has been published 
using primary AML primary patient samples167-169. 
 
1.4 Objectives  
 
The objectives of this work were: 
(1): To establish the use of CSC and it’s variants technologies on AML cells from 
primary patient samples. 
(2): To identify new biomarkers to measure MRD and target antigens from primary 
AML patient samples. 
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2. Materials and methods 
 
2.1 Materials 
2.1.1 Chemicals and Kits 
 
Table 2-1. Chemicals and Kits 
 
Name Product No. Company 
Sodium (met)periodate (NaIO4) 30323-100 g Sigma-Aldrich 
Biocytin hydrazide ABD-3086 Biomol 
Tris base 93350-100 g Sigma-Aldrich 
Magnesium chloride hexahydrate (MgCl2·6H2O) 13152-1 kg Sigma-Aldrich 
MES hydrate M8250-250 g Sigma-Aldrich 
Sodium chloride (NaCl) S1679-500 g Sigma-Aldrich 
Sucrose 16104-1 kg Sigma-Aldrich 
Ammonium bicarbonate (NH4HCO3) 11213-1 kg-R Sigma-Aldrich 
RapiGest 186001860-1 mg Waters 
Tris (2-carboxyethyl)phosphine hydrochloride C4706-2 g Sigma-Aldrich 
Iodoacetamide I1149-5 g Sigma-Aldrich 
2,2'-Thiodiethanol 166782-100 g Sigma-Aldrich 
Sequence grade modified trypsin V5111-5X20 µg Promega 
Glycerol free PNGase F P0705 S-15000 units NEB 
Pierce™ Streptavidin Plus UltraLink™ Resin 53117-5 ml ThermoFisher 
EZ-Link™ Sulfo-NHS-SS-Biotin 21331-100 mg ThermoFisher 
Sodium bicarbonate(NaHCO3) 6885.2-500 g Carl Roth 
Sodium carbonate (Na2CO3) A135.1-500g Carl Roth 
DL-Dithiothreitol  43815-1 g Sigma-Aldrich 
HPLC Grade Water W/0110/PB17-2.5 L ThermoFisher 
Formic acid (HCOOH) 56302-10 X 1 ml Sigma-Aldrich 
Acetonitrile (CH3CN) 34967-250 ml Sigma-Aldrich 
LC-MS grade water 39253-1 l-R Sigma-Aldrich 
Ultrapure Water Cay400000-4 L Biomol 
Glycerol G5516-500 ml Sigma-Aldrich 
Triton™ X-100 T9284-500 ml Sigma-Aldrich 
Fetal Bovine Serum  10270-106-500 ml ThermoFisher 
Horse Serum H1270-500 ml Sigma-Aldrich 
Recombinant Human G-CSF (rh-G-CSF) 300-23-1 mg PeproTech 
Recombinant Human IL-3 (rh-IL-3) 200-03-1 mg PeproTech 
Recombinant Human TPO (rh-TPO) 300-18-1 mg PeproTech 
2-Mercaptoethanol (14.3 M) M6250-100 ml Sigma-Aldrich 
Penicillin-Streptomycin-Glutamine (100X) 10378016-100 ml ThermoFisher 
Pierce™ Bovine Serum Albumin Standard 23209-10 x 1 ml ThermoFisher 
Pierce™ BCA Protein Assay Kit 23227-500 ml ThermoFisher 
Pierce™ C18 Spin Columns 89870-25 columns ThermoFisher 
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2.1.2 Solutions, Mediums and Buffers (Commercial) 
 
Table 2-2. Solutions, Mediums and Buffers (Commercial) 
 
Name Product No. Company 
Phosphoric Acid 438081-500 ml Sigma-Aldrich 
Sodium hydroxide solution (4 mol/l) T198.1-1 L Carl Roth 
Hydrochloric acid (6 mol/l) 0281.1-1 L Carl Roth 
UltraPure™ 0.5M EDTA, pH 8.0 15575-038-100 ml ThermoFisher 
HEPES buffer (1M)  15630-080-100 ml ThermoFisher 
DPBS P04-36500-500 ml PAN-Biotech 
RPMI 1640 P04-16500-500 ml PAN-Biotech 
Alpha MEM Eagle P04-21500-500 ml PAN-Biotech 
 
2.1.3 Solutions, Mediums and Buffers (Handmade) 
 
Table 2-3. Solutions, Mediums and Buffers (Handmade) 
 
Name Preparation method 
R10 medium (10% FBS, 1% HEPES, 1% 
Penicillin-Streptomycin-Glutamine in 
RPMI 1640) 
Add 50 ml FBS, 5 ml of HEPES and 5 ml of 
Penicillin-Streptomycin-Glutamine into 500 ml RPMI 1640 
medium. Store at 4 °C. 
Blasts Base medium (12.5% 
FBS ,12.5% horse serum ,1% 
Penicillin-Streptomycin-Glutamine in 
ALPHA MEM Eagle Medium) 
Add 62.5 ml FBS, 62.5 ml of horse serum and 5 ml of 
Penicillin-Streptomycin-Glutamine into 500 ml ALPHA 
MEM Eagle Medium. Store at 4 °C. 
Long-Term culture medium (20 ng/ml 
of rh-G-CSF, rh-IL-3 and rh-TPO, 57.2 
μM -mercaptoethanol in Blasts Base 
medium) 
Add 2 µl (0.1 mg/ml) of rh-G-CSF, rh-IL-3 and rh-TPO to 
10 ml Blasts Base medium. Add 4 µl (1:100 dillution) of 
-mercaptoethanol. Mix and store at 4 °C. 
FACS buffer 500 ml DPBS, 1% bovine serum albumin (BSA), 0.1% 
sodium azide 
Glyco labeling buffer (PBS, pH=6.5) 500 ml DPBS, adjust the pH to 6.5 with 85% (w/v) 
Phosphoric Acid. Add 0.5 ml fetal bovine serum.  
NaIO4 stock solution (160 mM) Add 34 mg NaIO4 to 0.9 ml labeling buffer and make up to 
1 ml with labeling buffer. (Keep in dark) 
Biocytin hydrazide solution (5.4 mM) Add 25 mg biocytin hydrazide to 10 ml labeling buffer, mix 
and make up to 14 ml with labeling buffer. (Prepare 
before use) 
Iodoacetamide stock solution (500 mM) Add 92.48 mg iodoacetamide to 800 µl water, mix, and 
make up to 1 ml with water. Aliquot and store at  
−20°C. (Keep in dark) 
Lysine labeling buffer (2 mM 
sulfo-NHS-SS-biotin and 4 mM 
iodoacetamide) 
Add 5.55 mg sulfo-NHS-SS-biotin and 40 µl of 
iodoacetamide stock solution to 4.5 ml PBS, mix and 
make up to 5 ml with PBS. (Prepare before use) 
Hypotonic lysis buffer (Glyco-CSC) (10 
mM Tris pH=7.5, 0.5 mM MgCl2) 
Add 0.6 g Tris Base and 50.5 mg MgCl2·6H2O to 45 ml 
water. Mix and adjust the pH to 7.5 with 1M HCl. Make up 
to 50 ml with water. Store at 4 °C. 
Hypotonic lysis buffer (Lys-CSC) (10 
mM Tris pH=7.5, 0.5 mM MgCl2,10 mM 
iodoacetamide) 
Add 0.6 g Tris Base, 92.48 mg iodoacetamide and 50.5 
mg MgCl2·6H2O to 45 ml water. Mix and adjust the pH to 
7.5 with 1M HCl. Make up to 50 ml with water. Store at 
4 °C. (Keep in dark) 
MES stock solution (500 mM, pH=6)  Add 9.76 g MES hydrate to 80 ml water. Mix and adjust 
the pH to 6 with 1 M NaOH. Make up to 100 ml with water.  
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Membrane preparation buffer (50 mM 
MES pH=6, 10 mM MgCl2 , 450 mM 
NaCl, 280 mM sucrose) 
Add 2.03 g MgCl2·6H2O, 26.30 g NaCl, 95.84 g sucrose 
and 100 ml of the 500 mM MES stock solution pH=6 to 
700 ml water. Mix and make up to 1 L. Aliquot in 50 ml 
tubes and store at −20°C.  
Membrane wash buffer (25 mM 
Na2CO3) 
Add 0.265 g Na2CO3 to 90 ml water. Mix and make up to 
100 ml with water. 
Sucrose buffer (35% sucrose in 
membrane preparation buffer and 
water) 
Add 15.08 g sucrose to 20 ml water. Mix and make up to 
25 ml with water. Add 25 ml of Membrane preparation 
buffer. Store at −20°C. 
NH4HCO3 buffer (100 mM) Add 0.395 g NH4HCO3 to 45 ml water. Mix and make up 
to 50 ml with water. (Prepare before use) 
2,2-Thiodiethanol stock solution (100 
mM BHES) 
Add 12.22 mg BHES to 900 µl water. Mix and make up to 
1 ml. Store at −20°C 
RapiGest stock solution (1% (w/v) 
RapiGest surfactant) 
Add 1 mg RapiGest to 10 µl water. Mix and store at 4 °C. 
Tris (2-carboxyethyl) phosphine stock 
solution (100 mM TCEP) 
Add 28.66 mg TCEP to 900 µl water. Mix and make up to 
1 ml. Aliquot and store at −20°C. 
Digestion buffer (Glyco-CSC, 
Cys-Glyco-CSC) (100 mM NH4HCO3 , 1 
mM iodoacetamide, 1 mM BHES) 
Add 100 µl of BHES stock solution and 200 µl of 
iodoacetamide stock solution to 9 ml NH4HCO3. Make up 
to 10 ml with NH4HCO3. 
Digestion buffer (Lys-CSC) (100 mM  
NH4HCO3, 1.25 mM iodoacetamide, 1.25 
mM BHES, 2 mg/ml RapiGest.) 
Add 5 µl of BHES stock solution and 1 µl of 
iodoacetamide stock solution to 320 µl NH4HCO3. Mix 
and add 80 µl of RapiGest stock solution. (Keep in dark) 
NaCl washing buffer (5 M NaCl) Add 14.6 g NaCl to 30 ml water, mix and make up to 50 
ml with water.  
Detergent buffer (137 mM NaCl, 50 mM 
Tris pH=7.8, 10% glycerol, 0.5 mM 
EDTA pH 8, 0.1% Triton X-100) 
Add 0.606 g Tris base to 70 ml water and adjust pH to 7.8 
with 1 M HCl. Then, add 0.8 g NaCl, 10 ml glycerol, 0.1 ml 
EDTA stock solution, and 1 ml Triton X-100 and make up 
to 100 ml  with water.  
NaHCO3 washing buffer (100 mM 
NaHCO3, pH=11) 
Add 0.84 g NaHCO3 to 90 ml water. Adjust pH with 1 M 
NaOH and make up to 100 ml with water. (Prepare before 
use) 
Dithiothreitol (DTT) stock solution (100 
mM DTT) 
Add 15.4 mg DTT to 800 µl water. Mix and make up to 1 
ml. Aliquot and store at −20°C. 
Elution buffer (100 mM NH4HCO3 , 10 
mM TCEP, 1 mM DTT) 
Add 100 µl DTT stock solution and 200 µl TCEP stock 
solution to 9 ml NH4HCO3. Mix and make up to 10 ml with 
100 mM NH4HCO3 buffer. 
10% formic acid (10% (v/v) formic acid) Add 1 ml formic acid to 9 ml water. 
50% acetonitrile (LC-MS grade water, 
50% (v/v) acetonitrile, 0.1% (v/v) formic 
acid) 
Add 5 ml acetonitrile and 10 µl formic acid to 4.5 ml 
LC-MS grade water. Mix and make up to 10 ml with 
LC-MS grade water. 
80% acetonitrile (LC-MS grade water, 
80% (v/v) acetonitrile, 0.1% (v/v) formic 
acid) 
Add 8 ml acetonitrile and 10 µl formic acid to 1.5 ml 
LC-MS grade water. Mix and make up to 10 ml with 
LC-MS grade water. 
Sample buffer (LC-MS grade water, 5% 
(v/v) acetonitrile, 0.1% (v/v) formic 
acid) 
Add 0.5 ml acetonitrile and 10 µl formic acid to 9 ml 
LC-MS grade water. Mix and make up to 10 ml with 
LC-MS grade water. 
 
2.1.4 Instruments and Equipments 
 
Table 2-4. Instruments and Equipments 
 
Name Company 
5 ml, 15 ml and 50 ml Tubes  BD  
FACS tubes BD 
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1.5 ml and 2 ml Tubes  Eppendorf  
Ultracentrifuge Tubes (SW40) Seton Scientific 
pH Meter (MP225) METTLER TOLEDO 
Vortexer  Heidolph Instruments  
Mobicol “classic” column-M1002 Mobitec 
Filter (large) 35 μm pore size-M523515 Mobitec 
Countess™ Automated Cell Counter Invitrogen 
Glass 7 mL Dounce Tissue Grinder-357542 Wheaton 
Centrifuge-5920R Eppendorf 
Centrifuge-5417R Eppendorf 
Thermomixer-Comfort (1.5 ml) Eppendorf 
Ultracentrifuge-L70 Beckman 
Rotary mixer-LD-76 Labinco-BV 
Roll mixer-SRT6D Stuart 
Vacuum Concentrator Centrifuge (SpeedVac)-UNIVAPO 150 H Uniequip 
Bioruptor Diagenode 
LC-MS (Elite-velos-pro) ThermoScientific 
FACS (10-color Navios flow cytometer) Beckman Coulter 
 
2.1.5 Antibodies for FACS 
 
Table 2-5. Antibodies for FACS 
 
Name Product No. Company 
PE-CD172b Cat # 323906 BioLegend 
PE-CD148 Cat # 328708 BioLegend 
Brilliant Violet 421-CD49d Cat # 304321 BioLegend 
FITC-PLXA1 Cat #: abx107198 Abbexa 
PE-ITB7 Cat #: 321204 BioLegend 
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2.2 Methods 
2.2.1 Cell culture 
 
The AML cell line OCI-AML3 was maintained in RPMI1640 medium, supplemented 
with 10% fetal calf serum, 1% penicillin/streptomycin/glutamine and 0.005 mM 
2-mercaptoethanol. The cell suspension was kept in the incubator at 37°C, 5% CO2. 
 
2.2.2 Patient-derived xenograft (PDX) cells 
 
In cooperation with Prof. Dr. med. Irmela Jeremias (Group Leader of Apoptosis Group 
in Helmholtz Zentrum München), we collected 2 patient-derived xenograft (PDX) 
samples. The PDX cells were obtained from mice spleen as previously described170. 
Briefly, patient cells were transplanted i.v. into NSG mice. After 6 to 20 weeks, when 
mice showed clinical signs of illness, mice were sacrificed and PDX cells were 
isolated from bone marrow and spleen. PDX cells were either directly retransplated or 
frozen for later analyses or retransplantation.To amplify transgenic PDX cells, they 
were retransplanted into mice. Fresh PDX cells were incubated with hypotonic lysis 
buffer (Vcell:Vbuffer=1:2) for 10 minutes at room temperature to lysis the blood and 
spleen cells. Then, the sample was centrifuged at 500×g for 5 minutes. The pellet 
was resuspended in 50 ml labeling buffer. Around 108 cells were harvested, with a 
cell viability of 89% and 91% for PDX1 and PDX2, respectively. Fresh PDX cells were 
immediately performed with experiments following the improved CSC protocol. 
Patient characteristics were collected in Table 2-6.   
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2.2.3 Primary patient (PP) cells 
 
Peripheral blood (PB) and/or bone marrow (BM) samples were collected from primary 
diagnosis or relapsed AML patients after signed informed consent in accordance with 
the Declaration of Helsinki and approval by the Institutional Review Board of the 
Ludwig-Maximilians-University (Munich, Germany). Primary AML patient cells were 
isolated by gradient centrifugation and then stored in -80°C, -150°C or liquid nitrogen 
until further experiments were performed. Primary patient (PP) samples for CSC tests 
were subjected to the long-term cell culture workflow as reported previously with 
slight modifications52. Briefly, irradiated MS-5 cells were resuspended in blast 
medium and 2.5 x 105 cells /well were seeded on 6-well plates.  The plates were 
incubated at 37°C overnight to allow the cells to adhere to the plate. The primary 
patient cells were thawed and washed with pre-heated blasts basal medium (550 g, 5 
min). Cells were counted and washed one more time with blast medium.  Then the 
cell pellet was resuspended in blasts basal medium, and 20 ng / ml of IL-3, TPO and 
G-CSF + 57.2 μM -mercaptoethanol were added to the medium.  Then, the 
medium in the 6-well plate was carefully removed without scratching the feeder layer. 
1-1.5 x 107 cells/well were added into the plate. The cells were incubated at 37°C for 
3 days and then were collected, counted and subjected to the Glyco-CSC protocol. 
Patient characteristics are summarized in Table 2-6.   
 
Table 2-6. Patient characteristics for CSC experiments. 
 
Sample Sex 
Age 
(Y) 
FAB 
Disease 
Stage 
Cytogenetics 
NPM
1 
FLT3
-ITD 
ELN 
BM/
PB 
PDX 1 F 47 M4 
Relapse 
after SCT 
46,XX, ins(10;11) 
(p12;q23q23) 
WT WT Adv BM 
PDX 2 M 57 M4 
Primary 
Diagnosis 
46,XY,t(6;11) 
(q27;q23) 
WT WT Adv BM 
PP 01 F 35 M1 
Primary 
Diagnosis 
46,XX WT WT Fav BM 
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PP 03 F 28 M5 
Primary 
Diagnosis 
46,XX,t(11;19) 
(q23;p13.3) 
WT WT Adv BM 
PP 04 M 55 NA Relapse 46,XY WT WT NA PB 
PP 05 F 53 NA 
Primary 
Diagnosis 
46,XX Mut Mut NA BM 
PP 06 F 31 NA 
Primary 
Diagnosis 
46,XX,der(8)(8;21)(q
22;q22),der(22)t(8;22
)(q22;q1?3)[21] 
WT WT NA BM 
 
PDX (patient-derived xenograft); PP (Primary Patient); F (female); M (male); FAB 
(French–American–British classification system); SCT (stem cell transplantation); NPM1 
(nucleophosmin-1); WT (wildtype); Adv (adverse); Mut (mutated); FLT3 (Fms-related tyrosine kinase 
3); ITD (internal tandem duplication); ELN (European LeukemiaNet classification system); PB 
(peripheral blood); BM (bone marrow); NA (not available) 
 
 
2.2.4 CSC technology 
 
2.2.4.1 Original protocol 
Original standard Glyco-CSC and it’s variants (Cys-Glyco-CSC and Lys-CSC) 
technology were performed as previously described155,156. Briefly, about 108 cells 
were labeled with biocytin hydrazide (Glyco-CSC and Cys-Glyco-CSC, 10 ml, 6.5 mM) 
after the oxidation with NaIO4 (50 ml ,1.6 mM), or NHS-SS-biotin (Lys-CSC, 5 ml, 2 
mM). Afterwards, cells were lysis with Dounce homogenizer or bioruptor. 
Subsequently, surface proteins were collected by ultracentrifugation in a 1:1 ratio with 
membrane preparation buffer and hypotonic lysis buffer (Glyco-CSC and 
Cys-Glyco-CSC, 100,000×g, 60 minutes) or in a sucrose gradient (Lys-CSC, 
150,000×g, 60 minutes, collect the phase border containing plasma membranes into 
a new ultracentrifuge tube and fill the tube with hypotonic lysis buffer and then 
centrifuge at 200,000×g, 20 hours). Membrane protein pellets from Glyco-CSC and 
Cys-Glyco-CSC were incubated with 400 µl membrane wash buffer and then filled 
with hypotonic lysis buffer and centrifuged at 100,000×g, 60 minutes. Membrane 
protein pellets were completely collected into a new 2 ml tube and added 340 µl of 
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100 mM NH4HCO3 buffer and 40 µl of 1% RapiGest stock solution (Glyco-CSC and 
Cys-Glyco-CSC) or 320 µl of digestion buffer and 80 µl of 1% RapiGest stock solution 
(Lys-CSC), then were completely dissolved by indirect sonication. Protein 
concentrations were determined by BCA kit. For Glyco-CSC samples, membrane 
proteins were reduced by TCEP (8 µl, 100 mM, 30 minutes) and then alkylated by 
iodoacetamide (12 µl, 500mM, 30 minutes). While for Lys-CSC and optionally for 
Cys-Glyco-CSC samples, 1 µl PNGase F were added to solubilize and de-glycosylate 
the membrane proteins. The pre-treated membrane proteins were then digested 
overnight with trypsin at a ratio of trypsin: protein=1:50. The membrane proteins in the 
digestion were captured by affinity streptavidin beads and then released by 1 µl of 
glycerol-free PNGase F (Glyco-CSC and Cys-Glyco-CSC) or by reduction agents 
(cysteine contained peptides in Cys-Glyco-CSC and Lys-CSC ). Those peptides were 
then desalted and washed in C18 columns and concentrated in a SpeedVac 
concentrator. The complete dried peptides were resuspended in 20 µl of sample 
buffer and stored at -20°C for further LC-MS detection.  
In summary, the differences between Cys-Glyco-CSC and Glyco-CSC are that the 
Cys-Glyco-CSC skips the protein reduction and alkylation step and instead releases 
cysteine peptides by chemical reduction from the solid phase. Lys-CSC is also 
differing from Glyco-CSC in biotin labeling, ultracentrifugation and peptides release 
steps. The systematic workflow of CSC and it’s variants (Cys-Glyco-CSC and 
Lys-CSC) technology are illustrated in Figure 2-1. 
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Figure 2-1. Workflow of Cell Surface Capturing (CSC) technology and it's 2 variants
(Cys-Glyco-CSC and Lys-CSC). Modified from Wollscheid et al., Nat Biotechnol., 2009 and 
Elschenbroich et al., Exp Rev Pro., 2010. 
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2.2.4.2 Modifications to the protocol 
Several strategies were applied to improve the original Glyco-CSC protocol in our lab. 
Experimental modifications are listed in the following Table 2-7. Cys-Glyco-CSC was 
performed using the same modifications (No.3 through No. 6) as Glyco-CSC. Since 
the Lys-CSC protocol uses a different biotin derivative for labeling, strategies only 
modifications No.4 through No.6 were applied to the Lys-CSC protocol.  
 
Table 2-7. Strategies to improve the original CSC protocol. 
 
Modification 
No. 
Protocol Description 
1 Technical Control (without biocytin hydrazide treated) 
2 Original Glyco-CSC protocol 
3 Optimization ①: lower concentration of biocytin hydrazide (5.4 mM) 
4 Optimization ②: Optimization ① + bioruptor (instead of homogenizer) 
5 Optimization ③: Optimization ② + homogenizer + 2 times digestion (firstly 2 hours, 
then overnight) 
6 Optimization ④: Optimization ③ + digestion buffer (instead of pure NH4HCO3) 
 
 
2.2.5 LC-MS: 
 
Peptides in the sample were separated with an on-line 70 minutes reversed-phase 
nano HP-LC and analyzed on-line with a velos-pro orbitrap. MS1 spectra were 
acquired at 120000 resolution in data-dependent acquisition mode (top 10) and MS2 
spectra at low resolution in the ion trap. The activation time was 10 ms; the AGC 
target value 104 ions; the maximum injection time 100 ms and the minimum ion count 
500. Each sample was analyzed twice and the resulting technical replicates 
averaged. 
Raw files were analyzed with MaxQuant using N-deamidation, protein n-terminal 
acetylation and methionine oxidation as a variable modification. 
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Carbamidomethylation on cysteines was used as a fixed modification. A maximum 
precursor mass error of 4.5 ppm and a fragment mass error of 0.5 Da were allowed. 
The final peptide and protein list were filtered at a 1% FDR. As database the whole 
reviewed human proteome from UniProt August-2015 was used. 
The MaxQuant table containing the identified N-deamidations was processed further 
by incorporating annotations from UniProt and the Cell Surface Protein Atlas. Each 
deamidation was validated as and n-glycosylation based on the following criteria: i) 
the deamidation occurred in a NXS\T motif and had a MaxQuant localization 
probability greater than 0.75; ii) the deamidation occurred in a protein with at least 
one TM domain and/or signal peptide; and iii) the NXS\T motif did not overlap with a 
transmembrane (TM) domain. In this study, TM represented proteins with 
transmembrane domains or signal peptide, or that were present in the Cell Surface 
Protein Atlas, or that were annotated as Plasma Membrane proteins in Gene 
Ontology. Intensities between different samples were compared at the deamidation 
site level and deamidated-protein level. For the former n-glycosylations at the same 
site but in different tryptic peptides were summed. For the latter n-glycosylations at 
the same protein were averaged. Intensities were then log2-transformed and median 
normalization between samples was applied. Clustering at the protein level was done 
using hiearchical clustering either using Euclidean distance or Cosine correlation 
distance. Edges in the network plot with a cosine correlation lower than 0.85 were 
filtered out. Finally, gene enrichment analysis was performed using DAVID. 
Each of the samples were tested twice or three times. Intensity of the identified 
peptides were merged as average. 
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2.2.6 Flow cytometry 
 
Peripheral blood (PB) or bone marrow (BM) aspirate samples of AML patients at 
initial diagnosis were collected for flow cytometric analysis. All samples were 
collected after written informed consent in accordance with the Declaration of Helsinki 
and approval by the Institutional Review Board of the Ludwig Maximilian University 
Munich. Patient characteristics are summarized in Table 2-9. 
Antibody panel for the expression of candidate markers are shown in Table 2-8. 
Primary AML patient samples were analyzed by flow cytometry in the Laboratory of 
Leukemia Diagnostics of the Department of Internal Medicine III. Briefly, patient 
samples were thawed, cells were washed once with PBS and resuspended in FACS 
buffer. 106 cells in 100 µl of FACS buffer were used per tube. Appropriate amount of 
antibody or isotype control were added into the tube. Data was acquired using a 
Navios flow cytometer (Beckman Coulter, Brea, CA, USA). 
Antigen expression intensity was determined by median fluorescence intensity (MFI) 
ratio. The MFI ratio is calculated by dividing the MFI value of the antigen-specific 
antibody by the MFI value of the respective isotype control, as previously described52. 
Positive expression was defined as MFI ratio ≥1.5. MFI values were determined using 
FlowJo software (Version 9.8.5) (Tree Star Inc., Ashland, Oregon). 
2.2.7 Statistical analysis 
Intensity based absolute quantification (iBAQ) of protein was calculated as the sum of 
all peptide peak intensities divided by the number of theoretically observable tryptic 
peptides. 
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Table 2-8. Surfaceome panel for FACS detection. 
 
Tube FITC PE ECD PC7 
Alexa Fluor 
750 
KO 
Brilliant Violet  
421 
Isotype IgG1 IgG1 IgG1 IgG1 IgG1 CD45 IgG1 
1 CD38 SIRBL (CD172b) CD34 CD33  CD45 ITGA4 (CD49d) 
2 CD38 PTPRJ (CD148) CD34 CD33  CD45  
3 PLXA1 ITB7 CD34 CD33 CD38 CD45  
 
 
Table 2-9. Patient characteristics for FACS tests. 
 
 
 
 
 
Patient 
No. 
Sex 
Age 
(Y) 
FAB Blasts Cytogenetics 
NPM
1 
FLT3-IT
D 
ELN BM/PB 
1 F 69 M4 68% 46,XX Mut FLT-ITD
(low) 
Fav BM 
2 M 68 NA 32% NA Mut FLT-ITD
(low) 
Fav BM 
3 F 78 NA 20% 46,XX  Mut WT Fav PB 
4 M 86 M5b 47% 46,XY Mut WT Fav BM 
5 M 52 M3 41% 46,XY,t(15;17)(q24;q
21)[7]/46,XY,der(15)t
(15;17)(q24;q21),ider
(17)(q10)t(15;17)(q2
4;q21)[8]/46,XY[1] 
WT WT Int-I BM 
6 M 68 M1 65% 46,XY WT WT Int-I BM 
7 M 78 NA 21% 46,XY WT WT Int-I BM 
8 F 59 M1 77% 46,XX Mut Mut Fav BM 
9 M 78 NA 38% 46,XY WT WT Int-I BM 
10 F 80 M2 23% 46,XX WT WT Adv  BM 
11 F 31 M5 32% 46,XX Mut WT Fav BM 
12 F 60 M1 88% 46,XX WT WT Int-I BM 
13 M 50 NA 26% NA Mut WT Fav BM 
14 F 61 M4 54% 46,XX,der(6)t(6;13)(p
2?1;q?)[6]/46,XX[4] 
WT Mut Int-I PB 
15 F 41 NA NA NA WT WT Int-I PB 
16 M 32 M5a 96% 46,XY,t(9;11)(p21.3;
q23.3)[3]/55,sl,+3,+8,
+der(11)t(9;11)(p21.3
;q23.3),+12,+13,+14,
+18,+19,+20[13] 
WT WT Int-I BM 
17 M 68 NA 36% 46,XY[20] WT WT Adv BM 
18 F 87 M2 84% 46,XX[20] Mut FLT3-IT
D(high) 
Int -I  BM 
19 F 54 NA 40% 46,XX,t(3;3)(q21.3;q
26.2)[10]/46,XX[1].is
h 
der(2)t(2;11)(q3?7;q2
3)(KMT2A+)[3/14] 
WT WT Adv BM 
20 M 46 NA 59% NA NA NA NA BM 
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Statistical  data  were  analyzed using GraphPad  Prism  7.1  (GraphPad  software,  La 
Jolla. CA).  Data  is displayed as mean  ±  standard  error of  the mean (SEM),  using 
Two-tailed  Student’s t test to  determine  statistical  significance. Graphs  were 
generated with GraphPad Prism 7.1 (GraphPad software, La Jolla.CA), R Studio (R 
Studio, Boston, USA) and Adobe Illustrator CS6 (Adobe Systems, San José, USA). 
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3. Results 
 
 
3.1 Surfaceome study on AML cell line and patient samples 
3.1.1 Modifications to the Glyco-CSC protocol 
 
 
  
 
  
 
  
 
  
  
 
 
  
Initially,  we performed the original Glyco-CSC technology to capture N-glycosylated
158 160proteins using the OCI-AML3 cell line as described previously - . The protocol did 
work  well  with  good  peptides  intensity  detected  and  very  little  noise  (Figure  3-1  A). 
216  of  peptides digested from  125  N-glycosylated  proteins  were  identified. 54  were 
annotated as CD antigens. PANTHER association of the identified proteins revealed 
receptor  function  in about  1/3 of  the  proteins (Figure  3-1  B).  While  these  initial 
results  were  encouraging,  the  number  of  identified  proteins  of these  results  lacked
behind  other  publications  on  AML cell  lines,  where 237  and  230  proteins  were
160identified in HL-60 and NB4 cell lines, respectively . Moreover, only about 54% of 
identified proteins showed a mass shift (of 0.984 Da) at N-residues associated with 
N-glycosylated  and  had  TM  domains  or signal  peptide  annotated  in  UniProt, 
indicating  that  the  specificity  was lower  than  expected.  Therefore, we  employed 
strategies to improve the standard protocol in order to increase the specificity of the 
technology and generate more surface proteins.
Cell viability  during  the  oxidation  step  is  very  important  to  make  sure  the  targeted 
proteins are cell surface glycoproteins. Ensuring high viability avoids the possibility of 
chemical  reaction  between  sodium  periodate  and  intracellular  glycoproteins  caused 
by cell  lysis  or  permeabilized  membranes.  In  our  experiments, despite  slightly 
decreased  cell  numbers,  high cell  viability was  maintained  before cell  lysis was 
performed  (Supplemental information, Figure  S1  A  and  B). Comparable  data were
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also found in HL-60 cell line. As a benchmark CD33, a myeloid marker found on >99% 
of AML samples, was also detected in both two cell lines (Data from HL-60 was not 
shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. N-glycosylated proteins identified with original Glyco-CSC technology. (A) 
Distribution of identified glycosylated peptides on OCI-AML3 cell line. (B) PANTHER molecular 
function of identified surface proteins. 
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3.1.2 Strategies to improve the original Glyco-CSC protocol 
 
In order to improve the experimental CSC protocol, we introduced several 
modifications (Table 2-7). After the vicinal diol groups on glycoproteins were oxidized 
to aldehyde functions by periodate, biocytin hydrazide can covalently link to the 
aldehydes and form the hydrazone. In out initial experiments, we detected cell 
aggregation during this step, which was eliminated by lowering the concentration of 
biocytin hydrazide (5.4 mM) since we found cell aggregation during our experiments, 
after we add it to the cell suspension or during the incubation. Sonication using a 
bioruptor and followed by cell homogenization assured the complete lysis of cells and 
increased our yield of membrane proteins after ultracentrifugation. Then, double 
digestion with trypsin and replacement of pure NH4HCO3 solution with digestion 
buffer (100 mM NH4HCO3, 1 mM iodoacetamide, 1 mM 2,2’-thiodiethanol) increased 
the peptide yield retrieved from LC-MS.  
To evaluate the specificity of our modified method, we relied on the detection of the 
deamidation reaction detected by a mass shift (of 0.984 Da) at N-residues. 
Furthermore, the deamidation might be reduced by the three-dimensional structure of 
proteins and thus it can be enhanced by alkylation, tryptic digestion, and reduction171. 
Figure 3-2 shows the number of deamidation sites and the Loc. Prob. (probability of 
the PTM being localized at the claimed position, recommended threshold ≥0.75) of 
detected peptides. No glycosylated peptides were detected in our technical control 
without biocytin hydrazide (test NO. 1). Samples treated with lower concentration of 
biocytin hydrazide resulted in a slightly lower number of deamidation sites than the 
original concentration (test NO. 3 and test NO. 2, respectively). However, since cell 
aggregation affect the following cell lysis negatively and resulted in a decreased 
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amount of membrane protein and thus impacting specificity (data not shown), we 
preferred the modified protocol in the following experiments (test NO. 3). The number 
of deamidation sites increased in test group NO.4, where we performed cell lysis 
using the bioruptor rather than Dounce homogenizer, compared to the former 2 
groups. Double digestion further improved the yield. Finally, the use of  digestion 
buffer in test NO.6 worked better than pure NH4HCO3 in maintaining the peptides. 
In summary, more than 500 deamidation sites, which represent 252 proteins, were 
identified using our final, modified protocol.  In addition, the specificity of the 
technology was also increased. 80.4% of all identified proteins contained 
N-glycosylations and a transmembrane domain or a signal peptide annotated in 
UniProt compared to only 54% using the original protocol. Furhermore, 90.3% of the 
N-glycosylated proteins were annotated in UniProt as glycoproteins and 61.9% were 
annotated as plasma membrane proteins in Gene Ontology. These results showed 
the relative enrichment for N-glycosylated cell surface proteins in our study. 
 
 
 
 
 
 
 
 
 
 
A 
N
O
. 1
N
O
. 2
N
O
. 3
N
O
. 4
N
O
. 5
N
O
. 6
0
200
400
600
N
u
m
b
e
r 
o
f 
d
e
a
m
id
a
ti
o
n
 s
it
e
s
CD proteins
Non-CD proteins
Results 
 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-2. N-glycosylated  peptides  identified  by improved  strategies. (A) Deamidation  sites 
detected on  OCI-AML3  cell  line with  different  improved strategies. (B) Probability  of  the 
post-translational  modification  (PTM)  being  localized  at  the  claimed  position  (Loc.  Prob., 
recommended  threshold ≥ 0.75)  of  identified  peptides  in  each  group.  Peptides  representing  CD 
proteins  (labelling  with  green  column)  listed  on  the  left  while  Non-CD proteins  (labelling  with  brown 
column) listed on the right. 
 
3.1.3 Surfaceome study on patient sample (PDX1) with improved Glyco-CSC protocol 
 
In order to assure the effectiveness and robustness of the improved Glyco-CSC 
protocol, we began by employing the technology using a patient derived xenograft 
sample. 293 surface proteins were identified in this sample, slightly more than the 
from the OCI-AML3 cell line using our modified protocol (Figure 3-3 A). Similarly, 
almost the same percentage of CD and non-CD proteins were identified in the two 
samples (Figure 3-3 B). Comparable PANTHER protein classes172, including 
receptors, signaling molecules, cell adhesion molecules and immunity proteins,  
were detected in these 2 samples (Figure 3-3 C). Abundance of identified protein was 
calculated as the sum of all peptide peak intensities divided by the number of the 
observed peptides in our experiments. Proteins were divided into 4 clusters by their 
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expression level (log2 (Average of Abundance)). Cluster 1 showed proteins with low 
expression in both samples. Conversely, cluster 4 represents proteins with high 
expression in both samples (Figure 3-3 D). In fact, many well-known surface CD 
antigens, such as CD33 (P20138), CD45 (P08575), CD123 (P26951) and CD244 
(Q9BZW8) were clustered in cluster 4 in our study. CD64 (P12314) and CLL-1 
(Q5QGZ9) are two important surface markers for the differentiation of monocytes 
from myeloid progenitors173. CD64 showed high expression in both OCI-AML3 and 
PDX1 samples, while CLL-1 high expressed only in the PDX1 sample in our study. 
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Figure 3-3 Cell surface proteins identified by improved Glyco-CSC technology.  Totally 384 
membrane proteins identified in 2 different cell types. (A) Area-proportional Venn diagram
174
 of 
overlapping membrane proteins identified in OCI-AML3 and PDX cells. (B) More than one third of 
identified membrane proteins were annotated as CD antigens in both samples. (C) PANTHER proteins 
classifications of membrane proteins identified in AML samples (http://pantherdb.org/). (D) Expression 
level (log2 (Average of abundance)) and hierarchical clusters of identified membrane proteins in 
OCI-AML3 and PDX samples. Green colour indicated high protein expression level, while red colour 
indicated low protein expression level.  
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3.1.4 Surfaceome study on OCI-AML3 cell line with improved Glyco-CSC, 
Cys-Glyco-CSC and Lys-CSC protocol 
 
Buidling on the the results obtained above from the OCI-AML3 cell line and PDX1 
sample using the Glyco-CSC technology, we next used the OCI-AML3 cell line to 
investigate the improved Cys-Glyco-CSC (n=3) and Lys-CSC (n=3) protocol, in 
parallel with additional 3 replicates of Glyco-CSC on this cell line. The step-to-step 
protocol is depicted in Figure 2-1 and the modifications are listed in Table 2-7. Each 
biological replicate was tested twice. Results from each technology were merged 
together.  
496 cell surface proteins were identified using the Glyco-CSC protocol, 231 proteins 
were identified using Cys-Glyco-CSC, while only 126 proteins were identified with 
Lys-CSC (Figure 3-4 A). A network diagram illustrates the details of identified proteins 
using the 3 improved CSC protocols (Figure 3-4 B). Overall, 119 CD antigens (Green 
color nodes) were identified and 483 proteins were annotated as non-CD proteins. 
The width of the links indicated the peptide number of each identified proteins, 
ranging from 1 to 32. The size of the nodes increased with the number of TM domains, 
ranging from 0 to 36. Nevertheless, the size will not increase if there were more than 
10 TM domains in that protein. 
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Figure 3-4 Comparison network of membrane proteins identified with improved Glyco-CSC, 
Cys-Glyco-CSC and Lys-CSC technology in OCI-AML3. (A) Area-proportional Venn diagram
174
 of 
overlapping 602 membrane proteins identified with improved Glyco-CSC and its variant technology 
with OCI-AML3 cell line. (B) Nodes represented for CD proteins were in green colour and non-CD 
proteins were in brown colour. The thickness of the links connecting two nodes was proportional to the 
number of peptides identified for that protein. The size of the node indicated the number of 
transmembrane domains (TMs) in the protein. Proteins with more than 9 TMs were limited in size to 
10. 
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3.1.5 Surfaceome study on clinical patient samples 
 
Maintaining high viability of primary patient AML blasts while gathering sufficient cell 
numbers necessary for the CSC protocol is a significant challenge. Our pre-liminary 
work using clinical patient samples directly with our improved Glyco-CSC protocol 
also provided unsatisfied results. Specifically, cell viability decreased rapidly during 
oxidation and biotynilation steps before the cell lysis was performed (data not shown). 
Thus, in this study, we used two well studied methods to improve viability of clinical 
patient samples for to interrogate the AML surfaceome. 
We used two PDX samples (PDX1 and PDX2) from Prof. Dr. med. Irmela Jeremias’ 
group in Helmholtz Zentrum München170. For sample PDX1, we were able to perform 
the Glyco-CSC (n=1) and Cys-Glyco-CSC (n=1) protocol, while for PDX2, we were 
performed Glyco-CSC (n=1) only due to limited cell numbers isolated from mice 
spleen. Additionally, six clinical primary patient samples (PP01-PP06) were used to 
perform our improved Glyco-CSC protocol. Results from PP02 were retrospectively 
excluded in this study due to a change in the final clinical diagnosis from AML to ALL. 
To improve cell viability prior to CSC experiments, primary patient samples were 
maintained in a long-term culture system established in our lab52. Clinical 
characteristics of patient samples used for this study are listed in Table 2-6. Taken 
together, data from 22 samples (OCI-AML3 with Glyco-CSC (n=6, test NO.6 plus 5 
replicates), OCI-AML3 with Cys-Glyco-CSC (n=5), OCI-AML3 with Lys-CSC (n=3), 
PDX1 with Glyco-CSC (n=1), PDX1 with Cys-Glyco-CSC (n=1), PDX2 with 
Glyco-CSC (n=1), PP01 with Glyco-CSC (n=1), PP03 with Glyco-CSC (n=1), PP04 
with Glyco-CSC (n=1), PP05 with Glyco-CSC (n=1) and PP06 with Glyco-CSC (n=1)) 
Results 
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were merged together as surfaceome results in this study. Intensity based absolute 
quantification (iBAQ) of protein was calculated as described in the Methods.  
22.9% (165) of all identified proteins had CD annotations (Figure 3-5 A). In total, 23 
types of PANTHER protein classes were associated with the 719 identified proteins 
(Figure 3-5 B). Furthermore, those 719 proteins were involved in 75 pathways found 
in the PANTHER database (Supplemental information, Figure S3). Most notably, 
these included the integrin signaling pathway (P00034) and inflammation related 
pathway (P00031), followed by the Wnt signaling pathway (P00057). Cancer 
associate and immune cells responses pathways, like p53 pathway (P00059), 
JAK/STAT signaling pathway (P00038), Wnt signaling pathway (P00057), 
Interferon-gamma signaling pathway (P00035) and Interleukin signaling pathway 
(P00036), B cell activation (P00010) and T cell activation (P00053), were also 
detected in our study. Expression levels (log10 (Average of iBAQ)) of the 165 CD 
proteins are shown in Figure 3-6.  
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Figure 3-5. Totally 719 surface proteins identified with CSC and its variant technology in 1 AML 
cell line and 7 clinical samples.  (A) 165 CD proteins and 554 non-CD proteins were identified in 1 
AML cell line and 7 clinical patient samples with specific CSC technologies. (B) PANTHER proteins 
classifications of 719 membrane proteins identified in 8 AML samples (http://pantherdb.org/).  
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Figure 3-6. Expression of CD proteins identified in AML samples. Overview of all 165 CD antigens 
in 8 AML samples. Color of the heatmap indicated the value of log10 (Average of iBAQ). 
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3.2 Selection and verification of candidate surface markers 
3.2.1 85 candidate proteins were filtered from 719 proteins as AML cell surface 
targeted markers  
 
In order to curate a list of candidate markers we filtered the list of identified proteins to 
concentrate on those proteins which show low expression on healthy hematopoietic 
cells as well as other normal human tissues. To achieve this, we interrogated two 
databases to correlate gene expression of the 719 proteins on blood cells in different 
stages (BloodSpot) and on normal human tissues (Genotype-Tissue Expression 
Project (GTEx)). 
We eliminated those proteins that showed a median value (log2 (Expression)) of: (I), 
HSC_BM (Hematopoietic stem cells from bone marrow) <8; (II), early HPC_BM 
(Hematopoietic progenitor cells from bone marrow) <8 and (III), CD14+ 
monocytes<10. Next, we eliminated proteins which showed median of RPKM in 
normal tissues excluding whole blood and spleen of ≥ 20 (rule IV) in the GTEx 
database. 
For all of the 719 surface proteins, there was no  expressiondata for 64 genes in 
BloodSpot and 40 genes in GTEx, respectively. Figures 3-8 (A)-(C) show the log2 
(Expression) of 655 genes in different stages of normal human hematopoiesis found 
in the BloodSpot (HemaExplorer) database. Genes were clustered by expression 
within the groups “HSC_BM” (Figure 3-8 A), “early HPC_BM” (Figure 3-8 B) and 
“CD14+ monocytes” (Figure 3-8 C), respectively. Accordingly, Figures 3-8 D illustrate 
the expression values (RPKM) of 679 genes in normal human tissues, excluded 
spleen and whole blood. Expression of all 719 proteins identified in our samples as 
determined by LC-MS/MS and calculated as log10 (Average of iBAQ) is depicted in 
Results 
 58 
Figure 3-8 E with values ranging from 0 to 8. 354 protein were identified (log10 
(Average of iBAQ)>0) in at least 4 out of 8 samples, thus we only considered these 
proteins (rule V). Taken all five filter rules together, 85 cell surface proteins were 
selected as candidate biomarkers for further study on AML (Figure 3-8 F). 
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Figure 3-7. CD33 gene expression in hematopoietic cells, AML petients samples and normal 
human tissues. (A) Microarray data showed the expression level of CD33 in hematopoietic cells (left) 
and in AML patients (right). Data obtained from BloodSpot (http://servers.binf.ku.dk/bloodspot/) and 
violin diagram was generated with R. (B) RNA sequencing data of CD33 expression in normal human 
tissues. Data was downloaded from GTEx (https://gtexportal.org/home/) and violin diagram was 
generated with R Studio.  
Abbreviations for Figure 3-7 A: AML complex., AML complex aberrant karyotype; AML inv(16), AML 
with inv(16)/t(16;16); AML MLL, AML with t(11q23)/MLL; AML normal karyotype., AML with normal 
karyotype + other abnormalities.; AML t(8;21), AML with t(8;21); AML t(15;17), AML with t(15;17).  
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Figure 3-8. Integrated strategies to investigate new AML-associated markers from 719 
identified surface proteins. Two databases were invited for further analyzation of potential new 
markers. Figure (A)-(C) showed the expression of 655 genes in hematopoietic cells at different 
maturation stages (Normal human hematopoiesis (HemaExplorer) based on curated microarray data 
(BloodSpot database: http://servers.binf.ku.dk/bloodspot/). Genes were hierarchical clustered by the 
value of log2 (expression). 436 and 437 targets were filtered out with strategy 1 and 2: median of log2 
(expression) in HSC_BM<8 (A) and Early HPC_BM<8 (B), respectively. 522 targets were filtered out 
with strategy 3: median of log2 (expression) in CD14
+
 monocytes<10 (C). Figure (D) demonstrated the 
expression of 679 genes in normal tissues based on RNA sequencing data (GTEx database: 
https://gtexportal.org/home/). Genes were hierarchical clustered by the value of RPKM. 283 
candidates were filtered out with with strategy 4: RPKM of all other normal tissues (exclude two cell 
lines (EBV-transformed lymphocytes and Transformed fibroblasts), the whole blood and spleen) <20 in 
the GTEx database. Figure (E) described the expression level of all 719 proteins identified in our 
samples, with specific CSC technology. Proteins were hierarchical clustered by the value of log10 
(Average of iBAQ). With strategy 5: commonly expressed in AML samples, 354 proteins were 
identified in no less than 4 out of 8 samples. (F) Symmetric Venn diagram
175
 of five strategies above to 
select new candidate surface targets, which resulted in 85 candidates for further study on AML cell 
lines or patient samples.  
 
Abbreviations for Figure 3-8 B: B cells, CD19
+
 B cells; CMP, Common myeloid progenitor cell; early 
HPC_BM, Hematopoietic progenitor cells from bone marrow; GMP, Granulocyte monocyte progenitors; 
HSC_BM, Hematopoietic stem cells from bone marrow; mDC, CD11c
+
 myeloid dendritic cells; MEP, 
Megakaryocyte-erythroid progenitor cell; MY_BM, Myelocyte from bone marrow; NK cells, CD56
+
 
natural killer cells; pDC, CD123
+
 plasmacytoid dendritic cells; PM_BM, Promyelocyte from bone 
marrow; PMN_BM, Polymorphonuclear cells from bone marrow; PMN_PB, Polymorphonuclear cells 
from peripheral blood.  
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3.2.2 5 potential markers selected for further study on clinical samples 
 
Finally, 3 CD proteins and 2 non-CD proteins were manually selected for further 
investigation following an extensive literature research based on novelty on potential 
for immunotherapeutic targeting. Expression levels of our 5 candidate markers and 6 
well-known AML targeted-therapy markers also detected in our samples are depicted 
in Figure 3-9. 5 out of these 6 markers were identified in at least 6 AML of our 
samples, further validating our modified CSC protocol.   
 
 
Figure 3-9. Protein expression of 5 new selected candidate markers and 6 novel markers in 8 
groups of AML samples. O00241 and Q5TFQ8 belong to the same family, CD172b. 5 candidate 
markers, including CD49d, CD148, CD172b, PLXA1 and ITB7 were selected for further clinical 
detection on AML patient samples. 5 out of 6 novel AML targets (exclude TIM3) were identified in 
75%-100% of our samples, which also indicate the modified CSC protocol worked efficiently in our lab. 
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Figure 3-10. Schematic representation of identified surface proteins from AML samples. 5 new 
candidate markers (A) and 5 on-going studied proteins (B) were submitted to the protein database
  "Protter" (http://wlab.ethz.ch/protter/#). Peptides identified from each protein were highlighted in red. 
PTMs, variants and disulfide bonds were rounded in green, yellow and blue color, respectively. Brown 
band represented the membrane. All identified peptides were from extracellular particle of relative
proteins.
Potential AML therapy markers, such as CD33, CD123, CD135, CD244 and CL12A,
also have been identified in most (75%-100%) of our samples. However, we did not
176identify TIM3, which is an interesting antigen to target stem cells of AML , in any of 
our samples (Figure 3-9). The most possible reason might be the sequence of amino 
acids and the structure of the protein. There is a N-glycosylation for TIM3 at residue 
172. The closest disulfide bonds to residue 172 might occur at residues 110 and 109, 
but there are many lysines/argines in between which can be cleaved by trypsin. So 
the chance of retrieving TIM-3 by piggy-peptides (Cys-Glyco CSC and Lys-CSC), or 
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putative  N-glycosylation (Glyco-CSC) is  either non-existent  or  of  low  abundance
based  on  the  mechanisms  of  CSC  technologies156,160 (Supplemental information, 
Figure S4).
Peptides  identified  with  CSC  and  its  variant  technologies  within  the  protein  context 
from our 5 novel candidate markers as well as the 5 more established AML targets 
were reconfirmed  using  the  protein  database “Protter”  (http://wlab.ethz.ch/protter/#)
and labelled in red (Figure 3-10 A and B). All peptides identified in our samples were 
from the extracellular region of the proteins. These results also indicate that the CSC 
technologies worked efficiently in our lab and we chose appropriate strategies to filter 
candidate AML markers. 
 
3.2.3 Flow cytometry analysis of 5 candidate markers with AML patient samples 
 
To confirm the expression of our candidate markers, we performed multicolor flow 
cytometry analysis on independent AML samples in our clinical laboratory. Samples 
were stained with corresponded antibodies and isotype controls. Gating strategy of 
blast cells are shown in Figure 3-11 A. Median fluorescence intensity (MFI) ratio was 
used to measure the antigen expression intensity and it was calculated as described 
previously52 (Figure 3-11 B).  
MFI ratio value showed varying degrees of surface antigen density on AML patient 
samples (Figure 3-11 C). Most patients were positive for CD148 (90.0%, mean MFI 
ratio value=12.39, n=10), CD172b (65.0%, mean MFI ratio value=3.87, n=20), ITGA4 
(72.7%, mean MFI ratio value=8.86, n=11) and ITGB7 (75.0%, mean MFI ratio 
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  value=5.03, n=20);  but remained negative for   PLXNA1 (70.0%,  mean   MFI  
ratio  value=1.48, n=20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3-11. FACS analysis of 5 candidate antigens with AML patient samples. Flow cytometric 
gating strategy of blast cells (A) and calculation of MFI Ratio (B). Antigen expression of 5 candidate 
surface markers was illustrated as MFI ratio and 4 out of 5 (80%) candidates got mean MFI ratio>1.5 
(C).
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3.3 Supplemental information  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Stable cell morphology during the process of Glyco-CSC protocol.  (A) Cells were 
slightly lost in both cell lines before cell lysis. (B) Cell viability was still very high after oxidation and 
biocytin hydrazide treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. The number of identified peptides decreased with the reduction of cell number. 
Peptides represented all peptides identified, not necessary only from surface proteins. Deamidations 
standed for sites that may have had a glycosylation. DeamidPeps were deamidated peptides; however, 
a single deamidation site can have more than 1 single tryptic peptide. Nglycosites and Nglycopep 
(Nglycopeptides) had similar meanings, but only for N-glycosylations. 
A B 
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Figure S3. PANTHER pathway analyzation of all 719 surface proteins identified from AML 
samples. Totally 75 pathways generated from PANTHER database. 7.4% and 6.5% of identified 
proteins involved in the integrin signaling pathway (P00034) and inflammation related pathway 
(P00031), respectively. Followed by the Wnt signaling pathway (P00057), which also had about 4.2% 
of proteins in this group. Many other immune response and cancer related pathways, such as B cell 
activation (P00010), T cell activation (P00053), p53 pathway (P00059), JAK/STAT signaling pathway 
(P00038), Interferon-gamma signaling pathway (P00035) and Interleukin signaling pathway (P00036) 
and so on, were also described in the figure. 
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Figure S4. Schematic representation of the extracellular domain of Hepatitis A virus cellular 
receptor 2 (HAVR2, TIM3). Extracellular sequences of TIM3 has 202 amino acids, including 6 
disulfide bonds, 2 PTMs and 1 variants. It has a TM domain from residue 203-223. Figure was 
modified from http://wlab.ethz.ch/protter/#. 
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4. Discussion 
 
Acute myeloid leukemia (AML) is a disease with poor prognosis signified by short 
overall survival and a high risk of relapse after therapy. The disease is highly 
heterogeneous and despite some improvements current therapeutic strategies have 
not been successful. During the past few years, considerable advances have been 
made in the field of immunotherapy, however immunotherapy of AML has been 
challenging52,114,115,177-180. 
All of these novel therapy strategies, such as CAR T cells therapy, antibody based 
therapies and vaccines require target antigens that are as specific as possible for the 
malignant cell. Many surface-bound target antigens, such as CD33, CD123, CD47, 
CD244, CD7, CD96, CD157, TIM3, FLT3 and CLL1, are known to be over-expressed 
on AML cells and leukemic stem cells (LSC)181-190. However, for all of these antigens 
there is considerable overlap with expression detected on healthy cells. 
CD33 and FLT3 are two well-characterised target antigens. CD33 is not a suitable 
target for conventional, non-conjugated antibody formats because of its rapid 
internalization into the cell upon receptor cross-linking. Moreover, CD33 is also high 
expressed in healthy cells, i.e. lung, spleen and whole blood. Recently, our group 
evaluated another candidate target, CD157, with a novel Fc-engineered antibody 
(MEN1112) in AML. MEN1112 could trigger NK cell-mediated cytotoxicity to against 
AML cell lines and primary AML cells185. In a similar study, Salih H.R. et al. also 
described another interesting target, CD133. In their study, monoclonal antibody 
293C3-SIDE made degranulation and lysis of CD133-positive primary AML cells by 
activation of NK cells191. More recently in 2018, Salih H.R. et al. and colleagues 
published another NK cells-related AML therapy strategy with checkpoint modulator 
Discussion 
 72 
OX40192. Taken those above and other researches, NK cells and its cell viability may 
play important role in AML immunotherapy193,194. Besides NK cells, regulatory T cells 
(Tregs) could be another candidate or auxiliary AML therapy strategy
195.  
 
4.1 In combination of improved CSC workflow with ex vivo co-culture system 
provided impressive surfaceome data in AML 
 
Because of the accessibility at the cell surface, there is great clinical interest to 
identify suitable surface antigens as therapeutic targets for cancer immunotherapy. A 
comprehensive analysis of the surface proteome promises to be helpful for the 
identification of additional targets, which may be considered for the development of 
antibody and CAR based immunotherapy in AML. However, until recently, a 
comprehensive mapping of the surface proteins from primary AML samples was 
technologically limited. 
Here in this study, we improved the original CSC protocol and it’s 2 variants to 
achieve this. The mass spectrometry-based CSC workflow capture bona fide cell 
surface proteins from living cells and provides the possibility to capture all surface 
proteins from any cell population. Wollscheid and colleagues described that as many 
as 95% of identified proteins were cell surface proteins155. In our study we adapted 
the protocol to increase the yield of identified proteins. Since we detected cell 
aggregation during the biotinylation step, we slightly reduced the concentration of 
hydrazide during this step for subsequent experiments. Several other modifications 
were made to increase the yield as well as the specificity of identified peptides, which 
include ultrasonic breakage, trypsinic digestion and a modified peptide digestion step 
(Table 2-7). Using our modified CSC protocol, we were able to double the yield of 
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identified proteins from AML cell lines, from initially 125 to 252. More importantly, the 
specificity of the protocol was significantly increased as well. 80.4% of all peptides 
identified with modified protocol fulfilled the criteria, a mass shift (of 0.984 Da)  
associated with successful N-glycosylation and had a transmembrane domain or 
signal peptide annotated in Uniprot, while only 54% of all peptides identified fulfilled 
these criteria in the original Glyco-CSC experiments. 
Other studies also showed promising results for quantitative proteomics, such as 
CSC in combination with stable-isotope labeling with amino acids in cell culture 
(SILAC) technique196, experimentally verified potential N-glycosylation sites which 
were not confirmed before197, and a similar assay to capture cell surface proteins with 
both lectin-based affinity and glycocapture on hydrazide resins198. However, as the 
periodate oxidation/hydrazide method is highly specific for detecting glycoproteins, 
the CSC workflow will not work for minority of proteins which are non-glycosylated, 
such as the lymphoma target antigen, CD20199. Another disadvantage of chemical 
oxidation related techniques is the high cell number required. In this study, we found 
both the number of deamidations and peptides had a sharp decline with the reduction 
of the cell number (Supplemental information, Figure S2). To overcome this difficulty 
and maintain high viability in our samples, we performed ex vivo co-culture system 
prior to our CSC workflow from primary AML patient samples52. 
In combination with the modified CSC-workflow and ex vivo co-culture system, 
surfaceome data from 22 tests of primary and cell line samples were generated in 
our lab. Atotal of 719 surface proteins were identified and 22.9% of them had CD 
annotations. Of them all, 23 PANTHER proteins classes, which involved 75 
PANTHER pathways were screened out (Figure 3-5 and Supplemental information, 
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Figure S3). Compare to our study, Bernd Wollscheid and his colleagues phenotyped 
more than 500 membrane proteins in two AML cell lines, HL-60 and NB4. However, 
they did not show any data from primary or relapsed AML patient samples160. In 
another surfaceome study, Dario Neri and colleagues identified about 320 
membrane proteins, less than half of our identifications, with cell surface biotinylation 
related methods from acute leukemia cell lines and a normal human granulocytes 
(polymorphonuclear cells/PMN)166. Taken together, all data described above 
suggested that the modified CSC-workflow plus ex vivo co-culture system worked 
efficiently in our lab for the study of surfaceome in primary AML samples. This study 
is, to our knowledge, the first large scale of surfaceome identification from AML 
clinical patient samples. 
 
4.2 5 suitable targets were selected for further clinical investigation 
 
Next, we aimed to identify new un-studied surface targets for further evaluation in 
AML. Two databases were interrogated to filter all 719 proteins we identified above: 
a gene expression database (BloodSpot) of all blood cells during the development, 
differentiation and maturation and a gene expression database (Genotype-Tissue 
Expression Project , GTEx) of all normal human tissues. We identified and calculated 
the expression levels of all identified proteins, excluded those with significant 
expression in healthy HSCs, HSPCs and most healthy tissues. Finally, we only 
considered those proteins detected by CSC in at least half of the primary patient 
samples. 85 proteins were filtered and then subjected to manual screening. Of note, 
several antigens currently under investigation for AML immunotherapy (i.e. CD33, 
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CD123, CD135, CLL-1) were detected by the method as well. 5 interesting candidate 
novel markers were selected for the following tests in AML primary patient samples. 
CD49d is a receptor for fibronectin and it may participate in cytolytic T-cell 
interactions with target cells. Most recently, two groups found it may also show 
positive characteristics in study on CLL/SLL200,201. CD148 is a transmembrane 
protein-tyrosine phosphatase with a single intracellular catalytic domain and an 
extracellular domain with structural similarities to cell adhesion molecules. Previous 
studies showed that CD148 was expressed but not functioning as a protein-tyrosine 
phosphatases for FLT3-ITD. The high ROS levels in FLT3 ITD–expressing cells led to 
partial inactivation of CD148 by reversible oxidation202. There were 3 proteins from 
signal-regulatory protein (SIRPB1, CD172b) family, identified in our samples (Figure 
3-6). CD172a acted as inhibitory receptor by interacting with a broadly expressed 
transmembrane protein CD47 also called the "don t́ eat me" signal203. Conversely, 
the molecular role of CD172g in immune response or cancer immunity is poorly 
understood to date. We have detected two isoforms of CD172b, signal-regulatory 
proteinβ -1 (O00241; Gene: SIRB1) and signal-regulatory proteinβ -1 isoform 3 
(Q5TFQ8; Gene: SIRBL). Data from SIRPα/β- and SIRPβ -specific MoAbs revealed 
low / absent expression on HSC204. Since the natural ligand for SIRPβ is unknown, 
the in vivo functional role of SIRPβ remains unresolved205. We chose CD172b for 
further study on AML patient blasts in this work. PLXA1 is a coreceptor for SEMA3A, 
SEMA3C, SEMA3F and SEMA6D. In Lewis lung carcinoma, Plxna1 knockdown 
caused an increased sensitivity to the EGFR-TKIs gefitinib and erlotinib206. 2 other 
members of the plexin family were detected to be differently regulated by ATRA. 
Increased protein abundances of CD232 (PLXC1) but decreased protein abundances 
of plexin D1 (PLXD1) were detected in both AML cell lines after ATRA stimulation160. 
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PLXA1 might be a potential target in AML therapy after forming dimer with 
NRP-1207,208. ITB7 forms the heterodimer LPAM-1 with CD49d and plays role in 
homing to bone marrow and inflammation209,210. Vedolizumab (trade name Entyvio) is 
a monoclonal antibody binds to integrin α4β7 (LPAM-1), which can be used to treat 
inflammatory bowel disease after failure of TNFα-antagonists211.  
Results of our FACS analysis on independent patient samples shows that except for  
PLXNA1 (mean MFI ratio value=1.48), all the other 4 candidate targets, ITGB7, 
CD172b, ITGA4 and CD148, were found on primary AML patients (>1.5), indicating 
that these candidates might be potential targets for further development of antibody, 
CAR T cells, immune checkpoints or even combinatorial targeting approach in AML. 
In conclusion, we successfully identified 719 surface proteins with the combination of 
modified CSC protocol with ex vivo culture system and subsequently selected 5 
candidate markers for test on primary AML patient. 4/5 showed expression in 
independent primary patient samples. These candidates will be further evaluated as 
potential targets for immunotherapy and targeted therapy strategy in AML. 
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